

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS	20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS

NEWS EXPRESS	DECEMBER 28	CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 18:21:55 ON 29 JAN 2004

FILE 'USPATFULL' ENTERED AT 18:21:55 ON 29 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 18:21:55 ON 29 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 18:21:55 ON 29 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 18:21:55 ON 29 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

=> s TIMP-1
L1 5340 TIMP-1

=> s cerebus protein
L2 1 CEREBUS PROTEIN

=> s brain derived neurotrophic factor or BDNF
L3 10853 BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF

=> s interferon alpha
L4 41802 INTERFERON ALPHA

=> s interferon beta
L5 14602 INTERFERON BETA

=> s albumin
L6 258098 ALBUMIN

=> s l6 and fusion
L7 30354 L6 AND FUSION

=> s l7 and l1
L8 214 L7 AND L1

=> s l7 and l2
L9 0 L7 AND L2

=> s l7 and l3
L10 636 L7 AND L3

=> s l7 and l4
L11 1550 L7 AND L4

=> s l7 and l5
L12 1361 L7 AND L5

=> s l6 and l2
L13 0 L6 AND L2

=> d l8 ti abs ibib 1-20

L8 ANSWER 1 OF 214 USPATFULL on STN
TI Molecules for diagnostics and therapeutics
AB The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing dithp for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compounds and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.

ACCESSION NUMBER: 2004:18785 USPATFULL
TITLE: Molecules for diagnostics and therapeutics
INVENTOR(S): Hodgson, David M., Ann Arbor, MI, UNITED STATES
Lincoln, Stephen E., Potomac, MD, UNITED STATES
Russo, Frank D., Sunnyvale, CA, UNITED STATES
Albany, Peter A., Berkeley, CA, UNITED STATES
Banville, Steve C., Sunnyvale, CA, UNITED STATES
Bratcher, Shawn R., Mountain View, CA, UNITED STATES
Dufour, Gerard E., Castro Valley, CA, UNITED STATES
Cohen, Howard J., Palo Alto, CA, UNITED STATES
Rosen, Bruce H., Menlo Park, CA, UNITED STATES
Chalup, Michael S., Livingston, TX, UNITED STATES
Jackson, Jennifer L., Santa Cruz, CA, UNITED STATES
Jones, Anissa L., San Jose, CA, UNITED STATES
Yu, Jimmy Y., Fremont, CA, UNITED STATES
Greenawalt, Lila B., San Jose, CA, UNITED STATES
Panzer, Scott R., Sunnyvale, CA, UNITED STATES
Roseberry Lincoln, Ann M., Potomac, MD, UNITED STATES
Wright, Rachel J., Merivale, NEW ZEALAND
PATENT ASSIGNEE(S): Daniels, Susan E., Mountain View, CA, UNITED STATES
Incyte Corporation, Palo Alto, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014087	A1	20040122
APPLICATION INFO.:	US 2003-378029	A1	20030228 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-980285, filed on 30 Nov 2001, PENDING A 371 of International Ser. No. WO 2000-US15404, filed on 31 May 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-147500P	19990805 (60)
	US 1999-147542P	19990805 (60)
	US 1999-147541P	19990805 (60)
	US 1999-147824P	19990805 (60)
	US 1999-147547P	19990805 (60)
	US 1999-147530P	19990805 (60)
	US 1999-147536P	19990805 (60)
	US 1999-147520P	19990805 (60)
	US 1999-147527P	19990805 (60)
	US 1999-147549P	19990805 (60)
	US 1999-147377P	19990804 (60)
	US 1999-147436P	19990804 (60)
	US 1999-137411P	19990603 (60)
	US 1999-137396P	19990603 (60)
	US 1999-137417P	19990603 (60)
	US 1999-137337P	19990603 (60)
	US 1999-137173P	19990602 (60)

US 1999-137114P 19990602 (60)
US 1999-137259P 19990602 (60)
US 1999-137113P 19990602 (60)
US 1999-137260P 19990602 (60)
US 1999-137258P 19990602 (60)
US 1999-137109P 19990602 (60)
US 1999-137161P 19990601 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 14819

L8 ANSWER 2 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)

US 2000-235834P	20000927	(60)
US 2000-234274P	20000921	(60)
US 2000-234223P	20000921	(60)
US 2000-228924P	20000830	(60)
US 2000-224518P	20000814	(60)
US 2000-236369P	20000929	(60)
US 2000-224519P	20000814	(60)
US 2000-220964P	20000726	(60)
US 2000-241809P	20001020	(60)
US 2000-249299P	20001117	(60)
US 2000-236327P	20000929	(60)
US 2000-241785P	20001020	(60)
US 2000-244617P	20001101	(60)
US 2000-225268P	20000814	(60)
US 2000-236368P	20000929	(60)
US 2000-251856P	20001208	(60)
US 2000-251868P	20001208	(60)
US 2000-229344P	20000901	(60)
US 2000-234997P	20000925	(60)
US 2000-229343P	20000901	(60)
US 2000-229345P	20000901	(60)
US 2000-229287P	20000901	(60)
US 2000-229513P	20000905	(60)
US 2000-231413P	20000908	(60)
US 2000-229509P	20000905	(60)
US 2000-236367P	20000929	(60)
US 2000-237039P	20001002	(60)
US 2000-237038P	20001002	(60)
US 2000-236370P	20000929	(60)
US 2000-236802P	20001002	(60)
US 2000-237037P	20001002	(60)
US 2000-237040P	20001002	(60)
US 2000-240960P	20001020	(60)
US 2000-239935P	20001013	(60)
US 2000-239937P	20001013	(60)
US 2000-241787P	20001020	(60)
US 2000-246474P	20001108	(60)
US 2000-246532P	20001108	(60)
US 2000-249216P	20001117	(60)
US 2000-249210P	20001117	(60)
US 2000-226681P	20000822	(60)
US 2000-225759P	20000814	(60)
US 2000-225213P	20000814	(60)
US 2000-227182P	20000822	(60)
US 2000-225214P	20000814	(60)
US 2000-235836P	20000927	(60)
US 2000-230438P	20000906	(60)
US 2000-215135P	20000630	(60)
US 2000-225266P	20000814	(60)
US 2000-249218P	20001117	(60)
US 2000-249208P	20001117	(60)
US 2000-249213P	20001117	(60)
US 2000-249212P	20001117	(60)
US 2000-249207P	20001117	(60)
US 2000-249245P	20001117	(60)
US 2000-249244P	20001117	(60)
US 2000-249217P	20001117	(60)
US 2000-249211P	20001117	(60)
US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)

US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

24

EXEMPLARY CLAIM:

1

LINE COUNT:

26776

L8 ANSWER 3 OF 214 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL

TITLE: **Albumin fusion** proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)

LINE COUNT: 25066

L8 ANSWER 4 OF 214 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins

AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL

TITLE: 7 Human ovarian and ovarian cancer associated proteins

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115

APPLICATION INFO.: US 2003-333900 A1 20030124 (10)
WO 2001-US8585 20010316
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 16023

L8 ANSWER 5 OF 214 USPATFULL on STN

TI Use of bioactive glass compositions to stimulate osteoblast production
AB Compositions comprising bioactive glass compositions or extracts thereof
which include ions in an appropriate concentration and ratio that they
enhance osteoblast production, and methods of preparation and use
thereof, are disclosed. The compositions can be included in implantable
devices that are capable of inducing tissue formation in autogeneic,
allogeneic and xenogeneic implants, for example as coatings and/or
matrix materials. Examples of such devices include prosthetic implants,
sutures, stents, screws, plates, tubes, and the like. Aqueous extracts
of the bioactive glass compositions, which extracts are capable of
stimulating osteoblast production, are also disclosed. The compositions
can be used, for example, to induce local tissue formation from a
progenitor cell in a mammal, for accelerating allograft repair in a
mammal, for promoting in vivo integration of an implantable prosthetic
device to enhance the bond strength between the prosthesis and the
existing target tissue at the joining site, and for treating tissue
degenerative conditions.

ACCESSION NUMBER: 2004:13078 USPATFULL
TITLE: Use of bioactive glass compositions to stimulate
osteoblast production
INVENTOR(S): Hench, Larry L, London, UNITED KINGDOM
Polak, Julia M, London, UNITED KINGDOM
Buttery, Lee D.k., London, UNITED KINGDOM
Xynos, Ioannis D, Nafplion, GREECE
Maroothynaden, Jason, London, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009598	A1	20040115
APPLICATION INFO.:	US 2003-332731	A1	20030707 (10)
	WO 2001-US21801		20010711
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1301		

L8 ANSWER 6 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel polynucleotides associated with
the plasma membrane, the polypeptides encoded by these polynucleotides
herein collectively referred to as "plasma membrane associated
antigens," and antibodies that immunospecifically bind these
polypeptides, and the use of such plasma membrane associated
polynucleotides, antigens, and antibodies for detecting, treating,
preventing and/or prognosing disorders related to these novel
polypeptides. More specifically, isolated nucleic acid molecules are
provided encoding novel plasma membrane associated polypeptides. Novel
polypeptides and antibodies that bind to these polypeptides are
provided. Also provided are vectors, host cells, and recombinant and

synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L8 ANSWER 7 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)
	US 2000-240960P	20001020 (60)
	US 2000-239935P	20001013 (60)
	US 2000-239937P	20001013 (60)
	US 2000-241787P	20001020 (60)
	US 2000-246474P	20001108 (60)
	US 2000-246532P	20001108 (60)
	US 2000-249216P	20001117 (60)

US 2000-249210P	20001117	(60)
US 2000-226681P	20000822	(60)
US 2000-225759P	20000814	(60)
US 2000-225213P	20000814	(60)
US 2000-227182P	20000822	(60)
US 2000-225214P	20000814	(60)
US 2000-235836P	20000927	(60)
US 2000-230438P	20000906	(60)
US 2000-215135P	20000630	(60)
US 2000-225266P	20000814	(60)
US 2000-249218P	20001117	(60)
US 2000-249208P	20001117	(60)
US 2000-249213P	20001117	(60)
US 2000-249212P	20001117	(60)
US 2000-249207P	20001117	(60)
US 2000-249245P	20001117	(60)
US 2000-249244P	20001117	(60)
US 2000-249217P	20001117	(60)
US 2000-249211P	20001117	(60)
US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)
US 2000-232399P	20000914	(60)
US 2000-232401P	20000914	(60)
US 2000-241808P	20001020	(60)
US 2000-241826P	20001020	(60)
US 2000-241786P	20001020	(60)
US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)

US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L8 ANSWER 8 OF 214 USPATFULL on STN

TI Methods for the treatment of carcinoma

AB The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of genes that are amplified in the genome of tumor cells, such as renal cell carcinoma. Such gene amplification is expected to be associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contribute to tumorigenesis. Accordingly, the proteins encoded by the amplified genes are believed to be useful targets for the diagnosis and/or treatment (including prevention) of certain cancers, such as renal cell carcinoma, and may act as predictors of the prognosis of tumor treatment. The present invention is directed to novel methods of diagnosing and treating tumor, such as renal cell carcinoma or Wilms tumor.

ACCESSION NUMBER: 2004:12653 USPATFULL
TITLE: Methods for the treatment of carcinoma
INVENTOR(S): Gerritsen, Mary E., San Mateo, CA, UNITED STATES
Peale, Franklin V., JR., San Carlos, CA, UNITED STATES
Wu, Thomas D., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009171	A1	20040115
APPLICATION INFO.:	US 2003-372683	A1	20030221 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-271690, filed on 16 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-344534P	20011018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	

LINE COUNT:

6662

L8 ANSWER 9 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

L8 ANSWER 10 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and

function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)

US 2000-236370P	20000929	(60)
US 2000-236802P	20001002	(60)
US 2000-237037P	20001002	(60)
US 2000-237040P	20001002	(60)
US 2000-240960P	20001020	(60)
US 2000-239935P	20001013	(60)
US 2000-239937P	20001013	(60)
US 2000-241787P	20001020	(60)
US 2000-246474P	20001108	(60)
US 2000-246532P	20001108	(60)
US 2000-249216P	20001117	(60)
US 2000-249210P	20001117	(60)
US 2000-226681P	20000822	(60)
US 2000-225759P	20000814	(60)
US 2000-225213P	20000814	(60)
US 2000-227182P	20000822	(60)
US 2000-225214P	20000814	(60)
US 2000-235836P	20000927	(60)
US 2000-230438P	20000906	(60)
US 2000-215135P	20000630	(60)
US 2000-225266P	20000814	(60)
US 2000-249218P	20001117	(60)
US 2000-249208P	20001117	(60)
US 2000-249213P	20001117	(60)
US 2000-249212P	20001117	(60)
US 2000-249207P	20001117	(60)
US 2000-249245P	20001117	(60)
US 2000-249244P	20001117	(60)
US 2000-249217P	20001117	(60)
US 2000-249211P	20001117	(60)
US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)
US 2000-232399P	20000914	(60)
US 2000-232401P	20000914	(60)
US 2000-241808P	20001020	(60)
US 2000-241826P	20001020	(60)
US 2000-241786P	20001020	(60)
US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)

US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 27694
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 214 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:7341 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S) : Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S) : Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)
	US 2000-231413P	20000908 (60)
	US 2000-229509P	20000905 (60)
	US 2000-236367P	20000929 (60)
	US 2000-237039P	20001002 (60)
	US 2000-237038P	20001002 (60)
	US 2000-236370P	20000929 (60)
	US 2000-236802P	20001002 (60)
	US 2000-237037P	20001002 (60)
	US 2000-237040P	20001002 (60)

US 2000-240960P	20001020	(60)
US 2000-239935P	20001013	(60)
US 2000-239937P	20001013	(60)
US 2000-241787P	20001020	(60)
US 2000-246474P	20001108	(60)
US 2000-246532P	20001108	(60)
US 2000-249216P	20001117	(60)
US 2000-249210P	20001117	(60)
US 2000-226681P	20000822	(60)
US 2000-225759P	20000814	(60)
US 2000-225213P	20000814	(60)
US 2000-227182P	20000822	(60)
US 2000-225214P	20000814	(60)
US 2000-235836P	20000927	(60)
US 2000-230438P	20000906	(60)
US 2000-215135P	20000630	(60)
US 2000-225266P	20000814	(60)
US 2000-249218P	20001117	(60)
US 2000-249208P	20001117	(60)
US 2000-249213P	20001117	(60)
US 2000-249212P	20001117	(60)
US 2000-249207P	20001117	(60)
US 2000-249245P	20001117	(60)
US 2000-249244P	20001117	(60)
US 2000-249217P	20001117	(60)
US 2000-249211P	20001117	(60)
US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)
US 2000-232399P	20000914	(60)
US 2000-232401P	20000914	(60)
US 2000-241808P	20001020	(60)
US 2000-241826P	20001020	(60)
US 2000-241786P	20001020	(60)
US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)

US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 214 USPATFULL on STN
TI Functional MRI agents for cancer imaging
AB The invention relates to novel magnetic resonance imaging contrast
agents for imaging cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:4285 USPATFULL
TITLE: Functional MRI agents for cancer imaging
INVENTOR(S): Meade, Thomas J., Altadena, CA, United States
Fraser, Scott, La Canada, CA, United States
Jacobs, Russell, Arcadia, CA, United States
PATENT ASSIGNEE(S): Research Corporation Technologies, Inc., Tucson, AZ,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673333	B1	20040106
APPLICATION INFO.:	US 2000-715859		20001117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201816P	20000504 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Hartley, Michael G.	
LEGAL REPRESENTATIVE:	Dorsey & Whitney LLP, Silva, Robin M., Kossiak, Renee M.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2422	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 214 USPATFULL on STN
TI 50 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL
TITLE: 50 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 33379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 214 USPATFULL on STN
TI Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
AB This invention relates to genes identified from human chromosome 20p13-p12, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and

isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and host cells comprising the disclosed nucleotide sequences, or fragments thereof, as well as antibodies that bind to the encoded polypeptides or peptides. Also related are ligands that modulate the activity of the disclosed genes or gene products. In addition, the invention relates to methods and compositions employing the disclosed nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases.

ACCESSION NUMBER: 2004:2447 USPATFULL
TITLE: Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
INVENTOR(S): Keith, Tim, Bedford, MA, UNITED STATES
Little, Randall D., Newtonville, MA, UNITED STATES
Eerdewegh, Paul Van, Weston, MA, UNITED STATES
Dupuis, Josee, Newton, MA, UNITED STATES
Del Mastro, Richard G., Norfolk, MA, UNITED STATES
Simon, Jason, Westfield, NJ, UNITED STATES
Allen, Kristin, Hopkinton, MA, UNITED STATES
Pandit, Sunil, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002470	A1	20040101
APPLICATION INFO.:	US 2002-277216	A1	20021017 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-126022, filed on 19 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-834597, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-548797, filed on 13 Apr 2000, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORGAN & FINNEGAN, L.L.P., 345 PARK AVENUE, NEW YORK, NY, 10154		
NUMBER OF CLAIMS:	45		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	162 Drawing Page(s)		
LINE COUNT:	15810		

L8 ANSWER 15 OF 214 USPATFULL on STN
TI Detection and modulation of Slit and roundabout (Robo) mediated angiogenesis and uses thereof
AB This invention is generally in the field of methods for diagnosis, treatment and prevention of various disorders involving the Slit2 mediated angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:335332 USPATFULL
TITLE: Detection and modulation of Slit and roundabout (Robo) mediated angiogenesis and uses thereof
INVENTOR(S): Geng, Jian-Guo, Portage, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003236210	A1	20031225
APPLICATION INFO.:	US 2003-386386	A1	20030310 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362485P	20020308 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Peng Chen, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332	

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1337
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334955 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)

US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)

US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS:

24

EXEMPLARY CLAIM:

1

LINE COUNT:

22457

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 214 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

Birse, Charles E., North Potomac, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-216880P	20000707 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-236367P	20000929 (60)
	US 2000-239937P	20001013 (60)
	US 2000-249210P	20001117 (60)
	US 2000-249211P	20001117 (60)
	US 2000-249214P	20001117 (60)
	US 2000-231243P	20000908 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)
	US 2000-249265P	20001117 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)

US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-179065P	20000131	(60)
US 2000-180628P	20000204	(60)
US 2000-214886P	20000628	(60)
US 2000-217487P	20000711	(60)
US 2000-225758P	20000814	(60)
US 2000-220963P	20000726	(60)
US 2000-217496P	20000711	(60)
US 2000-225447P	20000814	(60)
US 2000-218290P	20000714	(60)
US 2000-225757P	20000814	(60)
US 2000-226868P	20000822	(60)
US 2000-216647P	20000707	(60)
US 2000-225267P	20000814	(60)
US 2000-216880P	20000707	(60)
US 2000-225270P	20000814	(60)
US 2000-251869P	20001208	(60)
US 2000-235834P	20000927	(60)
US 2000-234274P	20000921	(60)
US 2000-234223P	20000921	(60)
US 2000-228924P	20000830	(60)
US 2000-224518P	20000814	(60)
US 2000-236369P	20000929	(60)
US 2000-224519P	20000814	(60)
US 2000-220964P	20000726	(60)
US 2000-241809P	20001020	(60)
US 2000-249299P	20001117	(60)
US 2000-236327P	20000929	(60)
US 2000-241785P	20001020	(60)
US 2000-244617P	20001101	(60)
US 2000-225268P	20000814	(60)
US 2000-236368P	20000929	(60)
US 2000-251856P	20001208	(60)
US 2000-251868P	20001208	(60)
US 2000-229344P	20000901	(60)
US 2000-234997P	20000925	(60)
US 2000-229343P	20000901	(60)
US 2000-229345P	20000901	(60)
US 2000-229287P	20000901	(60)
US 2000-229513P	20000905	(60)
US 2000-231413P	20000908	(60)
US 2000-229509P	20000905	(60)
US 2000-236367P	20000929	(60)
US 2000-237039P	20001002	(60)
US 2000-237038P	20001002	(60)
US 2000-236370P	20000929	(60)
US 2000-236802P	20001002	(60)
US 2000-237037P	20001002	(60)
US 2000-237040P	20001002	(60)
US 2000-240960P	20001020	(60)
US 2000-239935P	20001013	(60)
US 2000-239937P	20001013	(60)
US 2000-241787P	20001020	(60)
US 2000-246474P	20001108	(60)
US 2000-246532P	20001108	(60)
US 2000-249216P	20001117	(60)
US 2000-249210P	20001117	(60)
US 2000-226681P	20000822	(60)
US 2000-225759P	20000814	(60)
US 2000-225213P	20000814	(60)
US 2000-227182P	20000822	(60)
US 2000-225214P	20000814	(60)
US 2000-235836P	20000927	(60)

US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)

US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)
US 2000-179065P	20000131 (60)
US 2000-180628P	20000204 (60)
US 2000-214886P	20000628 (60)
US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)

US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)

US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 20415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 214 USPATFULL on STN
TI Compositions and methods for systemic inhibition of cartilage
degradation
AB Methods and compositions for inhibiting articular cartilage degradation.
The compositions preferably include multiple chondroprotective agents,
including at least one agent that promotes cartilage anabolic activity
and at least one agent that inhibits cartilage catabolism. The
compositions may also include one or more pain and inflammation
inhibitory agents. The compositions may be administered systemically,
such as to treat patients at risk of cartilage degradation at multiple
joints, and suitably may be formulated in a carrier or delivery vehicle
that is targeted to the joints. Alternatively the compositions may be
injected or infused directly into the joint.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:334713 USPATFULL
TITLE: Compositions and methods for systemic inhibition of
cartilage degradation
INVENTOR(S): Demopoulos, Gregory A., Mercer Island, WA, UNITED STATES
Palmer, Pamela Pierce, San Francisco, CA, UNITED STATES
Herz, Jeffrey M., Mill Creek, WA, UNITED STATES
PATENT ASSIGNEE(S): Omeros Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235589	A1	20031225
APPLICATION INFO.:	US 2003-356649	A1	20030131 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-31546, filed on 18 Jan 2002, PENDING A 371 of International Ser. No. WO 2000-US19864, filed on 21 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2001-839633, filed on 20 Apr 2001, PENDING Continuation-in-part of Ser. No. WO 1999-US26330, filed on 5 Nov 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US24625, filed on 20 Oct 1999, PENDING		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2002-353552P 20020201 (60)
 US 1999-144904P 19990721 (60)
 US 1998-107256P 19981105 (60)
 US 1998-105026P 19981020 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: OMEROS MEDICAL SYSTEMS, INC., 1420 FIFTH AVENUE, SUITE
 2675, SEATTLE, WA, 98101

NUMBER OF CLAIMS: 155
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 9 Drawing Page(s)
 LINE COUNT: 6575
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 214 USPATFULL on STN
 TI Nucleic acids, proteins, and antibodies
 AB The present invention relates to novel endocrine related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "endocrine antigens," and the use of such endocrine antigens for detecting disorders of the endocrine system, particularly the presence of cancers of the endocrine system and endocrine cancer metastases. More specifically, isolated endocrine associated nucleic acid molecules are provided encoding novel endocrine associated polypeptides. Novel endocrine polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human endocrine associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the endocrine system, including cancers of the endocrine system, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330759 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232975	A1	20031218
APPLICATION INFO.:	US 2002-74024	A1	20020214 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764895, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)

US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)

US 2000-249211P	20001117	(60)
US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)
US 2000-232399P	20000914	(60)
US 2000-232401P	20000914	(60)
US 2000-241808P	20001020	(60)
US 2000-241826P	20001020	(60)
US 2000-241786P	20001020	(60)
US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE:

Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 21828
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 214 USPATFULL on STN
TI Proteases
AB The invention provides human proteases (PRTS) and polynucleotides which
identify and encode PRTS. The invention also provides expression
vectors, host cells, antibodies, agonists, and antagonists. The
invention also provides methods for diagnosing, treating, or preventing
disorders associated with aberrant expression of PRTS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330138 USPATFULL
TITLE: Proteases
INVENTOR(S): Delegeane, Angelo M., Milpitas, CA, UNITED STATES
Gandhi, Ameena R., San Francisco, CA, UNITED STATES
Hafalia, April J. A., Santa Clara, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Arvizu, Chandra S., San Jose, CA, UNITED STATES
Tribouley, Catherine M., San Francisco, CA, UNITED STATES
Das, Debopriya, Mountain View, CA, UNITED STATES
Kallick, Deborah A., Portola Valley, CA, UNITED STATES
Nguyen, Danniell B., San Jose, CA, UNITED STATES
Lee, Ernestine A., Castro Valley, CA, UNITED STATES
Khan, Farrah A., Glen View, IL, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Au-Young, Janice, Brisbane, CA, UNITED STATES
Griffin, Jennifer A., Fremont, CA, UNITED STATES
Policky, Jennifer L., San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Thangavelu, Kavitha, Mountain View, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Kearney, Liam, San Francisco, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Borowsky, Mark L., Redwood City, CA, UNITED STATES
Sanjanwala, Madhusudan, Los Altos, CA, UNITED STATES
Yao, Monique G., Carmel, IN, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Chawla, Narinder K., Union City, CA, UNITED STATES
Lal, Preeti G., Santa Clara, CA, UNITED STATES
Lee, Sally, San Jose, CA, UNITED STATES
Todd, Stephen, San Francisco, CA, UNITED STATES
Lo, Terence P., Foster City, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Elliott, Vicki S., San Jose, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Lu, Yan, Palo Alto, CA, UNITED STATES
PATENT ASSIGNEE(S): Incyte Genomics, Inc., Palo Alto, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232349	A1	20031218
APPLICATION INFO.:	US 2002-274639	A1	20021018 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-US22397, filed on 17 Jul 2001, PENDING		

NUMBER	DATE
--------	------

```

-----
PRIORITY INFORMATION:  US 2000-220063P      20000721 (60)
                       US 2000-221680P      20000728 (60)
                       US 2000-223544P      20000804 (60)
                       US 2000-224717P      20000811 (60)
                       US 2000-225988P      20000816 (60)
                       US 2000-227568P      20000823 (60)

DOCUMENT TYPE:         Utility
FILE SEGMENT:         APPLICATION
LEGAL REPRESENTATIVE:  INCYTE CORPORATION (formerly known as Incyte, Genomics,
                       Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304

NUMBER OF CLAIMS:      86
EXEMPLARY CLAIM:       1
LINE COUNT:            8959
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55
ON 29 JAN 2004

```

L1      5340 S TIMP-1
L2      1 S CEREBUS PROTEIN
L3      10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4      41802 S INTERFERON ALPHA
L5      14602 S INTERFERON BETA
L6      258098 S ALBUMIN
L7      30354 S L6 AND FUSION
L8      214 S L7 AND L1
L9      0 S L7 AND L2
L10     636 S L7 AND L3
L11     1550 S L7 AND L4
L12     1361 S L7 AND L5
L13     0 S L6 AND L2

```

=> d l10 ti abs ibib 1-20

```

L10 ANSWER 1 OF 636  USPATFULL on STN
TI    Modulation of neural stem cells and neural progenitor cells
AB    The invention relates generally to methods of influencing central
      nervous system cells to produce progeny useful in the treatment of CNS
      disorders. More specifically, the invention includes methods of exposing
      a patient suffering from such a disorder to a reagent that modulates the
      proliferation, migration, differentiation and survival of central
      nervous system cells via S1P or LPA signaling. These methods are useful
      for reducing at least one symptom of the disorder.

```

```

ACCESSION NUMBER:      2004:19358  USPATFULL
TITLE:                 Modulation of neural stem cells and neural progenitor
                       cells
INVENTOR(S):           Lindquist, Per, Staltradsvagen 21, SWEDEN
                       Mercer, Alex, Staltradsvagen 15, SWEDEN
                       Ronnholm, Harriet, Tornslingan 8, ltr, SWEDEN
                       Wikstrom, Lilian, Stjarnfallsvagen 9, SWEDEN

```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014662	A1	20040122
APPLICATION INFO.:	US 2003-434943	A1	20030508 (10)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: US 2002-379114P 20020508 (60)
US 2002-393159P 20020702 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ivor R. Elrifi, Mintz, Levin, Cohn, Ferris,, Glovsky
and Popeo, P.C., 666 Third Avenue, 24th Floor, New
York, NY, 10017
NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 3175

L10 ANSWER 2 OF 636 USPATFULL on STN

TI Novel carcinoma-related genes and polypeptides and methods of use
thereof
AB Novel nucleic acids and polypeptides encoded thereby are provided that
are highly duplicated and overexpressed in squamous cell carcinomas of a
variety of tissues. Antibodies specific for binding the novel
polypeptides are also provided. The invention further discloses several
assays for gene duplication and overexpression of the novel gene and
excessive production of the novel polypeptide in a sample. These assays
permit assessing copy number in a sample from a subject, and contribute
to the diagnosis, prognosis and development of therapeutic strategy for
a pathology such as squamous cell carcinoma in a subject.

ACCESSION NUMBER: 2004:13021 USPATFULL
TITLE: Novel carcinoma-related genes and polypeptides and
methods of use thereof
INVENTOR(S): Singh, Bhuvanesh, New York, NY, UNITED STATES
Reddy, Pabbathi Gopal, Gangadhara Mandal, INDIA
Reddy, Pabbathi Thirumal, Gangadhara Mandal, INDIA LR
PATENT ASSIGNEE(S): Memorial Sloan-Kettering Cancer Center (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009541	A1	20040115
APPLICATION INFO.:	US 2003-361725	A1	20030210 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-355009P	20020208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Proteus Patent Practice LLC, P. O. Box 1867, New Haven, CT, 06508	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	6217	

L10 ANSWER 3 OF 636 USPATFULL on STN

TI Methods and reagents for dendritic localization of polynucleotides
AB The present invention provides for a recombinant nucleic acid molecule
comprising a region of a calcium-calmodulin dependent kinase II.alpha.
promoter operatively linked to a gene of interest. The region of a
calcium-calmodulin dependent kinase II.alpha.. promoter may comprise an
8.5 kilobase nucleic acid sequence which corresponds to the nucleic acid
sequence of ATCC Accession No. _____, designated pMM281. The present
invention also provides a human cell line which has been stably
transformed by a recombinant nucleic acid molecule comprising a gene of
interest operatively linked to a nucleic acid encoding a
calcium-calmodulin dependent kinase II.alpha. promoter region which has
a nucleotide sequence corresponding to the sequence of ATCC Accession

No. _____, designated pMM281. The present invention also provides for a transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII.alpha. promoter (ATCC Accession No. _____), introduced into the mammal, or an ancestor thereof, at an embryonic stage. Another embodiment of the present invention is a method of evaluating whether a compound is effective in treating symptoms of a neurological disorder in a subject which comprises: (a) administering the compound to the transgenic nonhuman mammal whose germ or somatic cells contain a nucleic acid molecule which encodes a gene of interest under the control of a CaMKII.alpha. promoter, and (b) comparing the neurological function the mammal in step (a) with neurological function of the transgenic mammal in the absence of the compound, thereby determining whether the compound is effective in treating symptoms of the neurological disorder in a subject.

ACCESSION NUMBER: 2004:12977 USPATFULL
 TITLE: Methods and reagents for dendritic localization of polynucleotides
 INVENTOR(S): Kandel, Eric R., Riverdale, NY, UNITED STATES
 Mayford, Mark, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009497	A1	20040115
APPLICATION INFO.:	US 2003-341999	A1	20030114 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-969137, filed on 12 Nov 1997, GRANTED, Pat. No. US 6509190		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	John P. White, Esq., Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	56 Drawing Page(s)		
LINE COUNT:	4900		

L10 ANSWER 4 OF 636 USPATFULL on STN
 TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
 AB The invention relates to compositions, kits, and methods for diagnosing, staging, prognosing, monitoring and treating human prostate cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer.

ACCESSION NUMBER: 2004:12961 USPATFULL
 TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
 INVENTOR(S): Schlegel, Robert, Auburndale, MA, UNITED STATES
 Endege, Wilson O., Norwood, MA, UNITED STATES
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009481	A1	20040115
APPLICATION INFO.:	US 2002-166883	A1	20020611 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-297285P	20010611 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 15572

L10 ANSWER 5 OF 636 USPATFULL on STN

TI Cardiostrophin and uses therefor

AB Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. CT-1 is shown to bind to and activate the receptor, LIFR.beta.. These CT-1 molecules are shown to influence hypertrophic activity, neurological activity, and other activities associated with receptor LIFR.beta.. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, neurological disorders, and other disorders associated with the LIFR.beta..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7778 USPATFULL

TITLE: Cardiostrophin and uses therefor

INVENTOR(S): Baker, Joffre, El Granada, CA, UNITED STATES
Chien, Kenneth, La Jolla, CA, UNITED STATES
King, Kathleen, Pacifica, CA, UNITED STATES
Pennica, Diane, Burlingame, CA, UNITED STATES
Wood, William, San Mateo, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006018	A1	20040108
APPLICATION INFO.:	US 2003-407303	A1	20030403 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-724772, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1997-797014, filed on 7 Feb 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-49998P	19960214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	5602	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 636 USPATFULL on STN

TI Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides

AB The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human DCAL-Hy polypeptides. Other aspects of the invention include vectors containing processes for producing novel human DCAL-Hy polypeptides, and antibodies specific for such polypeptides. Targeting DCAL-Hy using DCAL-Hy polypeptides, nucleic acids encoding for DCAL-Hy polypeptides, anti-DCAL-Hy antibodies, and other binding peptides and small molecules provides a method of killing or inhibiting that growth of cancer cells that express the DCAL-Hy protein. Methods of therapy and diagnosis of disorders associated with DCAL-Hy protein-expressing cells, such as DCAL-Hy, are described.

ACCESSION NUMBER: 2004:7358 USPATFULL

TITLE: Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides

INVENTOR(S): Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
Goodrich, Ryle W., Los Angeles, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005592	A1	20040108
APPLICATION INFO.:	US 2003-379127	A1	20030303 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-799451, filed on 5 Mar 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085		
NUMBER OF CLAIMS:	51		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Page(s)		
LINE COUNT:	7657		

L10 ANSWER 7 OF 636 USPATFULL on STN

TI Method for treating inflammation

AB A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7087 USPATFULL

TITLE: Method for treating inflammation

INVENTOR(S): Thompson, Penny, Snohomish, WA, UNITED STATES
Foster, Donald C., Lake Forest Park, WA, UNITED STATES
Xu, Wenfeng, Mukilteo, WA, UNITED STATES
Madden, Karen L., Bellevue, WA, UNITED STATES
Kelly, James D., Mercer Island, WA, UNITED STATES
Sprecher, Cindy A., Seattle, WA, UNITED STATES
Blumberg, Hal, Seattle, WA, UNITED STATES
Eagan, Maribeth A., Seattle, WA, UNITED STATES
Jaspers, Stephen R., Edmonds, WA, UNITED STATES
Chandrasekher, Yasmin A., Mercer Island, WA, UNITED STATES
Novak, Julia E., Bainbridge Island, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005320	A1	20040108
APPLICATION INFO.:	US 2003-424658	A1	20030428 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-746359, filed on 22 Dec 2000, GRANTED, Pat. No. US 6610286		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-171969P	19991223 (60)
	US 2000-213341P	20000622 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Shelby J. Walker, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA, 98102	

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 3489
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 636 USPATFULL on STN

TI Methods of therapy and diagnosis using immunotargeting of
CD84Hyl-expressing cells
AB Certain cells, including types of cancer cells such as lymphomas, are
capable of expressing high levels of CD84Hyl. Immunotargeting using
CD84Hyl polypeptides, nucleic acids encoding for CD84Hyl polypeptides
and anti-CD84Hyl antibodies provides a method of killing or inhibiting
that growth of CD84HY1Protein-expressing cancer cells. Methods of
immunotherapy and diagnosis of disorders associated with
CD84Hylprotein-expressing cells are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:7084 USPATFULL
TITLE: Methods of therapy and diagnosis using immunotargeting
of CD84Hyl-expressing cells
INVENTOR(S): Dederer, Douglas, Castro Valley, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2004005317	A1	20040108
APPLICATION INFO.:	US 2002-327413	A1	20021219 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-78080, filed on 15 Feb 2002, PENDING Continuation-in-part of Ser. No. WO 2001-US2613, filed on 25 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-645476, filed on 24 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	2703		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 636 USPATFULL on STN

TI Fc region variants
AB The present invention provides polypeptide Fc region variants and
oligonucleotides encoding Fc region variants. Specifically, the present
invention provides compositions comprising novel Fc region variants,
methods for identifying useful Fc region variants, and methods for
employing Fc region variants for treating disease.

ACCESSION NUMBER: 2004:2564 USPATFULL
TITLE: Fc region variants
INVENTOR(S): Watkins, Jeffry D., Olivenhain, CA, UNITED STATES
Allan, Barrett, Encinitas, CA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2004002587	A1	20040101
APPLICATION INFO.:	US 2003-370749	A1	20030220 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2002-358161P 20020220 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street,
San Francisco, CA, 94105
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 5292

L10 ANSWER 10 OF 636 USPATFULL on STN

TI Methods for making recombinant proteins using apoptosis inhibitors
AB The invention provided improved methods of making and producing
recombinant proteins in in vitro cultures of host cells using apoptosis
inhibitors. The use of one or more apoptosis inhibitors in the methods
can reduce apoptosis in the cell cultures and markedly improve yield of
the desired recombinant proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2118 USPATFULL
TITLE: Methods for making recombinant proteins using apoptosis
inhibitors
INVENTOR(S): Dixit, Vishva, Los Altos Hills, CA, UNITED STATES
Hamilton, Robert W., San Carlos, CA, UNITED STATES
Goor, Jana van de, Foster City, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002139	A1	20040101
APPLICATION INFO.:	US 2003-607882	A1	20030627 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-668924, filed on 25 Sep 2000, GRANTED, Pat. No. US 6586206		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156232P	19990927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Genentech, Inc., Attn: Diane L. Marschang, 1 DNA Way, South San Francisco, CA, 94080-4990	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	1549	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 636 USPATFULL on STN

TI Prevention or treatment of cancer using integrin alphavbeta3 antagonists
in combination with other agents
AB The present invention relates to methods and compositions designed for
the treatment, management or prevention of cancer. The methods of the
invention comprise the administration of an effective amount of one or
more antagonists of Integrin .alpha..sub.V.beta..sub.3 alone or in
combination with the administration of an effective amount of one or
more other agents useful for cancer therapy. The invention also provides
pharmaceutical compositions comprising one or more antagonists of
Integrin .alpha..sub.V.beta..sub.3 and/or one or more other agents
useful for cancer therapy. In particular, the invention is directed to
methods of treatment and prevention of cancer by the administration of a
therapeutically or prophylactically effective amount of one or more
antagonists of Integrin .alpha..sub.V.beta..sub.3 alone or in
combination with standard and experimental therapies for treatment or

prevention of cancer. Also included are methods for screening for epitope-specific Integrin .alpha..sub.V.beta..sub.3 antagonists which can be used according to the methods of the invention. In addition, methods for facilitating the use of Integrin .alpha..sub.V.beta..sub.3 antagonists in the analysis of Integrin .alpha..sub.V.beta..sub.3 expression in biopsies of animal model and clinical study samples are also contemplated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:1816 USPATFULL
TITLE: Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
INVENTOR(S): Woessner, Richard, Lafayette, CO, UNITED STATES
Kiener, Peter, Doylestown, PA, UNITED STATES
Dormitzer, Melissa, Germantown, MD, UNITED STATES
Walsh, William, Sharpsburg, MD, UNITED STATES
Heinrichs, Jon, North Potomac, MD, UNITED STATES
PATENT ASSIGNEE(S): MedImmune, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004001835	A1	20040101
APPLICATION INFO.:	US 2003-379189	A1	20030304 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-361859P	20020304 (60)
	US 2002-370398P	20020405 (60)
	US 2003-444265P	20030130 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	6588	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 636 USPATFULL on STN

TI Methods of treatment using specific binding agents of human angiopoietin-2
AB Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:335315 USPATFULL
TITLE: Methods of treatment using specific binding agents of human angiopoietin-2
INVENTOR(S): Oliner, Jonathan Daniel, Newbury Park, CA, UNITED STATES
Min, Hosung, Newbury Park, CA, UNITED STATES
PATENT ASSIGNEE(S): Amgen Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003236193	A1	20031225
APPLICATION INFO.:	US 2003-410998	A1	20030409 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-269695, filed on 10 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-414155P	20020927 (60)
	US 2001-328624P	20011011 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	U.S Patent Operations/[SNB], AMGEN, INC., Dept. 4300, M/S 27-4-A, One Amgen Center Drive, Thousand Oaks, CA, 91320-1799	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	9524	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L10 ANSWER 13 OF 636 USPATFULL on STN

TI Vascularized organized tissues and uses thereof

AB The invention relates to organized tissues that are implanted into an organism wherein they become vascularized. The invention also relates to methods of using an organized tissue that is vascularized following implantation into an organism, for delivery of a bioactive compound. The invention also relates to methods of producing an organized tissue that is vascularized following implantation into an organism.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334686 USPATFULL
 TITLE: Vascularized organized tissues and uses thereof
 INVENTOR(S): Vandeburgh, Herman H., Providence, RI, UNITED STATES
 Valentini, Robert F., Cranston, RI, UNITED STATES
 Wang, Xiao, Providence, RI, UNITED STATES
 Shansky, Janet, Barrington, RI, UNITED STATES
 Ferland, Paulette, Tiverton, RI, UNITED STATES
 DelTatto, Michael, Bristol, RI, UNITED STATES
 PATENT ASSIGNEE(S): Cell Based Delivery Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235561	A1	20031225
APPLICATION INFO.:	US 2002-281765	A1	20021028 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-391330P	20020625 (60)
	US 2002-399605P	20020730 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	85	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	5322	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L10 ANSWER 14 OF 636 USPATFULL on STN

TI Central airway administration for systemic delivery of therapeutics

AB The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products

have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

ACCESSION NUMBER: 2003:334661 USPATFULL
TITLE: Central airway administration for systemic delivery of therapeutics
INVENTOR(S): Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES
Simister, Neil E., Wellesley, MA, UNITED STATES
Bitonti, Alan J., Acton, MA, UNITED STATES
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., Boston, MA, UNITED STATES, 02115 (U.S. corporation)
Children's Medical Center Corporation, Boston, MA, UNITED STATES, 02115 (U.S. corporation)
Brandeis University, Waltham, MA, UNITED STATES, 02254 (U.S. corporation)
Syntonix Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235536	A1	20031225
APPLICATION INFO.:	US 2003-435608	A1	20030509 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364482P	20020315 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211	
NUMBER OF CLAIMS:	127	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	4042	

L10 ANSWER 15 OF 636 USPATFULL on STN

TI Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses

AB The invention provides a transgenic non-human animal expressing a perlecan encoding transgene. Also provided is a double-transgenic non-human animal expressing a perlecan and an amyloid encoding transgene. A method of screening for a compound which alters the rate or extent of amyloid deposition is additionally provided. The method consists of: (a) constructing a perlecan transgenic animal; (b) administering an effective amount of a test compound to said perlecan transgenic animal; and (c) determining whether said test compound alters the extent or rate of amyloid deposition. Finally, the invention provides a method of screening for a compound which alters the rate or extent of amyloid deposition. The method consists of: (a) constructing a perlecan/amyloid double-transgenic animal; (b) administering an effective amount of a test compound to said perlecan/amyloid double-transgenic animal; and (c) determining whether said test compound alters the extent o rate of amyloid deposition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:331452 USPATFULL
TITLE: Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
INVENTOR(S): Snow, Alan D., Lynnwood, WA, UNITED STATES
Fukuchi, Ken-Ichiro, Birmingham, AL, UNITED STATES
Hassell, John, Tampa, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003233669	A1	20031218
APPLICATION INFO.:	US 2003-384172	A1	20030305 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-536231, filed on 27 Mar 2000, GRANTED, Pat. No. US 6563016 Continuation of Ser. No. US 1997-870987, filed on 6 Jun 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-17830P	19960606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PATRICK M. DWYER, PROTEOTECH, INC, SUITE 114, 1818 WESTLAKE AVENUE N, SEATTLE, WA, 98109	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	25 Drawing Page(s)	
LINE COUNT:	2761	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L10 ANSWER 16 OF 636 USPATFULL on STN

TI Method for identifying compounds which affect synaptogenesis

AB A method is provided for identifying a compound which affects the formation of AMPA receptors into aggregates. A method is also provided for identifying a compound which affects the formation of synaptic connections. A method is provided for identifying a compound that modulates immediate early gene expression. A method is further provided for increasing the number of excitory synapses of a neuron, including introducing into the neuron a polynucleotide sequence encoding a Narp operatively linked to a promoter, or a Narp polypeptide, thereby increasing the number of excitory synapses of the neuron. A method is provided for treating a subject with a disorder associated with a decrease in a function or expression of Narp, including administering to the subject a therapeutically effective amount of a compound that augments Narp function or expression. A method is provided for treating a subject with a disorder associated with an increase in a function or expression of Narp, including administering to the subject a therapeutically effective amount of a compound that inhibits Narp function or expression. A method is provided for treating a patient having or at risk of having a disorder associated with decreased Narp expression. The method includes introducing into a cell of a patient having a disorder associated with decreased Narp expression or function a polynucleotide sequence encoding a Narp polypeptide operatively linked to a promoter. A method is provided for treating a subject having a deficiency in a neuron's immediate early gene responsiveness to a stimulus. The method includes administering a nucleic acid encoding a Narp polypeptide to said subject, wherein the administration results in amelioration of the deficiency.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330561 USPATFULL

TITLE: Method for identifying compounds which affect synaptogenesis

INVENTOR(S): Worley, Paul, Baltimore, MD, UNITED STATES
O'Brien, Richard, Baltimore, MD, UNITED STATES
Xu, DeSheng, Towson, MD, UNITED STATES
Huganir, Richard L., Baltimore, MD, UNITED STATES

PATENT ASSIGNEE(S): THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2003232776 A1 20031218
APPLICATION INFO.: US 2002-299957 A1 20021118 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-328710, filed on 9 Jun 1999, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GRAY CARY WARE & FREIDENRICH LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 636 USPATFULL on STN

TI Treatment of inner ear hair cells

AB Compositions, methods, and devices are provided for inducing or enhancing the growth, proliferation, regeneration of inner ear tissue, particularly inner ear hair cells. In addition, provided are compositions and methods for prophylactic or therapeutic treatment of a mammal afflicted with an inner ear disorder or condition, particularly for hearing impairments involving hair cell damage, loss, or degeneration, by administration of a therapeutically effective amount of IGF-1 or FGF-2, or their agonists, alone or in combination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330544 USPATFULL
TITLE: Treatment of inner ear hair cells
INVENTOR(S): Gao, Wei-Qiang, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232759	A1	20031218
APPLICATION INFO.:	US 2003-458039	A1	20030609 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-644368, filed on 23 Aug 2000, PENDING Division of Ser. No. US 1997-963596, filed on 31 Oct 1997, GRANTED, Pat. No. US 6156728		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HELLER EHRMAN WHITE & MCAULIFFE LLP, 275 MIDDLEFIELD ROAD, MENLO PARK, CA, 94025-3506		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	2082		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 18 OF 636 USPATFULL on STN

TI Proliferated cell lines and uses thereof

AB The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferation cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferation cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and

drug development.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330537 USPATFULL
TITLE: Proliferated cell lines and uses thereof
INVENTOR(S): Freeman, Thomas B., Tampa, FL, UNITED STATES
Caviedes, Pablo, Santiago, CHILE
Caviedes, Raul, Santiago, CHILE
Sanberg, Paul R., Spring Hill, FL, UNITED STATES
Cameron, Don F., Lutz, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232752	A1	20031218
APPLICATION INFO.:	US 2003-359854	A1	20030207 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-355157P	20020208 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669	
NUMBER OF CLAIMS:	93	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	30 Drawing Page(s)	
LINE COUNT:	4025	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 636 USPATFULL on STN

TI Molecules interacting with CASL (MICAL) polynucleotides, polypeptides, and methods of using the same
AB The present invention provides MICAL and MICAL-Like polypeptides and polynucleotides. Also provided are methods that for identifying agents that affect axon growth and placement. Furthermore, provided herein are methods for affecting axon growth and placement.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:330208 USPATFULL
TITLE: Molecules interacting with CASL (MICAL) polynucleotides, polypeptides, and methods of using the same
INVENTOR(S): Kolodkin, Alex L., Baltimore, MD, UNITED STATES
Terman, Jon R., Baltimore, MD, UNITED STATES
Mao, Tiany, Parkville, MD, UNITED STATES
Pasterkamp, Ronald J., Baltimore, MD, UNITED STATES
Yu, Hung-Hsiang, Lynnwood, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232419	A1	20031218
APPLICATION INFO.:	US 2003-359012	A1	20030204 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-354178P	20020204 (60)
	US 2002-384302P	20020530 (60)
	US 2002-388325P	20020613 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LISA A. HAILE, J.D., PH.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133	

NUMBER OF CLAIMS: 153
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 45 Drawing Page(s)
LINE COUNT: 10590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 20 OF 636 USPATFULL on STN

TI Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis

AB Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:329847 USPATFULL

TITLE: Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis

INVENTOR(S): Dubensky, Thomas W., JR., Del Mar, CA, UNITED STATES
Polo, John M., Encinitas, CA, UNITED STATES
Belli, Barbara A., San Diego, CA, UNITED STATES
Schlesinger, Sondra, St. Louis, MO, UNITED STATES
Drvga, Sergey A., Fort Collins, CO, UNITED STATES
Frolov, Ilya, St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232058	A1	20031218
APPLICATION INFO.:	US 2003-391441	A1	20030317 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-507362, filed on 18 Feb 2000, GRANTED, Pat. No. US 6592874 Division of Ser. No. US 1997-944465, filed on 6 Oct 1997, GRANTED, Pat. No. US 6451592 Continuation-in-part of Ser. No. US 1997-833148, filed on 4 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-679640, filed on 12 Jul 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-668953, filed on 24 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-628594, filed on 5 Apr 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	63 Drawing Page(s)		
LINE COUNT:	8258		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004

L1 5340 S TIMP-1

L2 1 S CEREBUS PROTEIN

L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
 L4 41802 S INTERFERON ALPHA
 L5 14602 S INTERFERON BETA
 L6 258098 S ALBUMIN
 L7 30354 S L6 AND FUSION
 L8 214 S L7 AND L1
 L9 0 S L7 AND L2
 L10 636 S L7 AND L3
 L11 1550 S L7 AND L4
 L12 1361 S L7 AND L5
 L13 0 S L6 AND L2

=> d l11 ti abs ibib 1-20

L11 ANSWER 1 OF 1550 MEDLINE on STN
 TI Pharmacokinetic and pharmacodynamic studies of a human serum
albumin-interferon-alpha fusion
 protein in cynomolgus monkeys.
 AB **Interferon-alpha** (IFN-alpha) is indicated for the
 treatment of certain viral infections including hepatitis B and C, and
 cancers such as melanoma. The short circulating half-life of unmodified
 IFN-alpha makes frequent dosing (daily or three times weekly) over an
 extended period (6-12 months or more) necessary. To improve the
 pharmacokinetics of IFN-alpha and decrease dosing frequency, IFN-alpha was
 fused to human serum **albumin** producing a new protein, **Albuferon**.
 In vitro comparisons of Albuferon and IFN-alpha showed similar antiviral
 and antiproliferative activities, although Albuferon was less potent on a
 molar basis than IFN-alpha. Pharmacokinetic and pharmacodynamic
 properties of the **fusion** protein were enhanced in monkeys.
 After a single intravenous injection (30 microg/kg,) clearance was 0.9
 ml/h/kg, and the terminal half-life was 68 h. After 30 microg/kg
 subcutaneous injection, apparent clearance (clearance divided by
 bioavailability) was 1.4 ml/h/kg, the terminal half-life was 93 h, and
 bioavailability was 64%. The rate of clearance of Albuferon was
 approximately 140-fold slower, and the half-life 18-fold longer, than for
 IFN-alpha given by the subcutaneous route in other monkey studies. Sera
 from Albuferon-treated monkeys demonstrated dose-related antiviral
 activity for > or =8 days based on an in vitro bioassay, whereas antiviral
 activity from IFN-alpha-treated animals was only slightly elevated
 relative to vehicle on day 0. Significant increases in
 2',5'-oligoadenylate synthetase mRNA relative to IFN-alpha- or
 vehicle-treated animals were maintained for > or =10 days after
 subcutaneous dosing. The improved pharmacokinetics of Albuferon are
 accompanied by an improved pharmacodynamic response suggesting that
 Albuferon may offer the benefits of less frequent dosing and a potentially
 improved efficacy profile compared with IFN-alpha.

ACCESSION NUMBER: 2002641106 MEDLINE
 DOCUMENT NUMBER: 22276264 PubMed ID: 12388634
 TITLE: Pharmacokinetic and pharmacodynamic studies of a human
 serum **albumin-interferon-alpha**
fusion protein in cynomolgus monkeys.
 AUTHOR: Osborn Blaire L; Olsen Henrik S; Nardelli Bernardetta;
 Murray James H; Zhou Joe X H; Garcia Andrew; Moody Gordon;
 Zaritskaya Liubov S; Sung Cynthia
 CORPORATE SOURCE: Human Genome Sciences, Inc., 9410 Key West Avenue,
 Rockville, MD 20850, USA.. blaire_osborn@hgsi.com
 SOURCE: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,
 (2002 Nov) 303 (2) 540-8.
 Journal code: 0376362. ISSN: 0022-3565.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200211

ENTRY DATE: Entered STN: 20021029
Last Updated on STN: 20021211
Entered Medline: 20021122

L11 ANSWER 2 OF 1550 USPATFULL on STN

TI Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
AB The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

ACCESSION NUMBER: 2004:21589 USPATFULL
TITLE: Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
INVENTOR(S): Gately, Maurice Kent, Montville, NJ, United States
Gubler, Ulrich Andreas, Glen Ridge, NJ, United States
Hulmes, Jeffrey David, Ringwood, NJ, United States
Podlaski, Frank John, New City, NY, United States
Stern, Alvin Seth, Passaic Park, NJ, United States
Chizzonite, Richard Anthony, South Kent, CT, United States
Pan, Yu-Ching Eugene, Pine Brook, NJ, United States
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6683046	B1	20040127
APPLICATION INFO.:	US 1995-459151		19950602 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-205011, filed on 2 Mar 1994, now abandoned Division of Ser. No. US 1992-857023, filed on 24 Mar 1992, now abandoned Continuation-in-part of Ser. No. US 1990-572284, filed on 27 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-520935, filed on 9 May 1990, now abandoned Continuation-in-part of Ser. No. US 1989-455708, filed on 22 Dec 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Romeo, David S.		
ASSISTANT EXAMINER:	Murphy, Joseph F.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	44 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	2745		

L11 ANSWER 3 OF 1550 USPATFULL on STN

TI Methods and compositions for interferon therapy
AB Methods and pharmaceutical compositions for administering interferon therapy to tissues or organs having an epithelial cell layer are provided. A recombinant adenoviral vector encoding an interferon gene is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the transduction of the cells of the target tissues or organs by the vector. The methods and combinations are useful in the treatment of cancers and other conditions

responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an adenoviral vector encoding alpha-interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 1,000 to 10,000 fold increase in interferon gene expression has been achieved by use of the combination of SYN3 with the recombinant adenoviral vector as compared to the use of the vector without SYN3.

ACCESSION NUMBER: 2004:19405 USPATFULL
 TITLE: Methods and compositions for interferon therapy
 INVENTOR(S): Engler, Heidrun, San Diego, CA, UNITED STATES
 Nagabhushan, Tattanahalli L., Parsippany, NJ, UNITED STATES
 Youngster, Stephen, Piscataway, NJ, UNITED STATES
 PATENT ASSIGNEE(S): Canji, Inc., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014709	A1	20040122
APPLICATION INFO.:	US 2003-455215	A1	20030604 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-55863, filed on 22 Jan 2002, PENDING Continuation of Ser. No. US 1998-112074, filed on 8 Jul 1998, GRANTED, Pat. No. US 6392069 Continuation-in-part of Ser. No. US 1997-889355, filed on 8 Jul 1997, PENDING Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244 Continuation-in-part of Ser. No. US 2003-454662, filed on 3 Jun 2003, PENDING Continuation of Ser. No. US 2000-650359, filed on 28 Aug 2000, ABANDONED Continuation of Ser. No. US 1997-779627, filed on 7 Jan 1997, GRANTED, Pat. No. US 6165779 Continuation-in-part of Ser. No. US 1996-584077, filed on 8 Jan 1996, GRANTED, Pat. No. US 5789244		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	2411		

L11 ANSWER 4 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
 AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:19345 USPATFULL
 TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
 INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
 Kinsella, Todd M., Fayetteville, NC, UNITED STATES
 Warner, Justin E., San Francisco, CA, UNITED STATES
 Kinoshita, Taisei, San Mateo, CA, UNITED STATES
 Bennett, Mark K., Moraga, CA, UNITED STATES
 Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014649	A1	20040122
APPLICATION INFO.:	US 2002-197919	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Page(s)		
LINE COUNT:	3468		

L11 ANSWER 5 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein

AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:19334 USPATFULL

TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein

INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
Kinsella, Todd M., Fayetteville, NC, UNITED STATES
Warner, Justin E., San Francisco, CA, UNITED STATES
Kinoshita, Taisei, San Mateo, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014638	A1	20040122
APPLICATION INFO.:	US 2002-197368	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	3569		

L11 ANSWER 6 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein

AB The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:18847 USPATFULL

TITLE: Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein

INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
Kinsella, Todd M., Fayetteville, NC, UNITED STATES

Warner, Justin E., San Francisco, CA, UNITED STATES
Kinoshita, Taisei, San Mateo, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014149	A1	20040122
APPLICATION INFO.:	US 2002-197962	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	53		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	3529		

L11 ANSWER 7 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated
IgE synthesis utilizing a chloride intracellular channel 1 protein

AB The present provides compounds capable of modulating IL-4
receptor-mediated IgE production, as well as IL-4 induced processes
associated therewith, methods and kits for identifying such compounds
that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate
analyte and methods of using the compounds in a variety of in vitro, in
vitro and ex vivo contexts.

ACCESSION NUMBER: 2004:18846 USPATFULL

TITLE: Methods of identifying compounds that modulate IL-4
receptor-mediated IgE synthesis utilizing a chloride
intracellular channel 1 protein

INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
Kinsella, Todd M., Fayetteville, NC, UNITED STATES
Warner, Justin E., San Francisco, CA, UNITED STATES
Kinoshita, Taisei, San Mateo, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014148	A1	20040122
APPLICATION INFO.:	US 2002-197945	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	57		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	3609		

L11 ANSWER 8 OF 1550 USPATFULL on STN

TI Methods of identifying compounds that modulate IL-4 receptor-mediated
IgE synthesis utilizing an adenosine kinase

AB The present provides compounds capable of modulating IL-4
receptor-mediated IgE production, as well as IL-4 induced processes
associated therewith, methods and kits for identifying such compounds
that utilize an adenosine kinase as a surrogate analyte and methods of
using the compounds in a variety of in vitro, in vitro and ex vivo
contexts.

ACCESSION NUMBER: 2004:18845 USPATFULL
TITLE: Methods of identifying compounds that modulate IL-4
receptor-mediated IgE synthesis utilizing an adenosine
kinase
INVENTOR(S): Masuda, Esteban, Menlo Park, CA, UNITED STATES
Kinsella, Todd M., Fayetteville, NC, UNITED STATES
Warner, Justin E., San Francisco, CA, UNITED STATES
Kinoshita, Taisei, San mateo, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
Anderson, David C., San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014147	A1	20040122
APPLICATION INFO.:	US 2002-197381	A1	20020716 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111		
NUMBER OF CLAIMS:	52		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	3513		

L11 ANSWER 9 OF 1550 USPATFULL on STN

TI Polynucleotide encoding a novel cysteine protease of the calpain
superfamily, Protease-42
AB The present invention provides novel polynucleotides encoding
Protease-42 polypeptides, fragments and homologues thereof. Also
provided are vectors, host cells, antibodies, and recombinant and
synthetic methods for producing said polypeptides. The invention further
relates to diagnostic and therapeutic methods for applying these novel
Protease-42 polypeptides to the diagnosis, treatment, and/or prevention
of various diseases and/or disorders related to these polypeptides. The
invention further relates to screening methods for identifying agonists
and antagonists of the polynucleotides and polypeptides of the present
invention.

ACCESSION NUMBER: 2004:18791 USPATFULL
TITLE: Polynucleotide encoding a novel cysteine protease of
the calpain superfamily, Protease-42
INVENTOR(S): Duclos, Franck, Washington Crossing, PA, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nayeem, Akbar, Newtown, PA, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014093	A1	20040122
APPLICATION INFO.:	US 2003-390585	A1	20030314 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364941P	20020314 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	19269	

L11 ANSWER 10 OF 1550 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)

US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)

US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 26776

L11 ANSWER 11 OF 1550 USPATFULL on STN
TI Treatment with anti-ErbB2 antibodies
AB The present application describes methods for treating cancer with
anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand
activation of an ErbB receptor.

ACCESSION NUMBER: 2004:18365 USPATFULL
TITLE: Treatment with anti-ErbB2 antibodies
INVENTOR(S): Kelsey, Stephen M., Montara, CA, UNITED STATES
Sliwowski, Mark X., San Carlos, CA, UNITED STATES
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2004013667 A1 20040122
 APPLICATION INFO.: US 2003-608626 A1 20030627 (10)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-268501, filed
 on 10 Oct 2002, PENDING Continuation-in-part of Ser.
 No. US 2000-602812, filed on 23 Jun 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-141316P	19990625 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	4076	

L11 ANSWER 12 OF 1550 USPATFULL on STN

TI Tumor necrosis factor receptors 6 alpha & 6 beta
 AB The present invention relates to novel Tumor Necrosis Factor Receptor
 proteins. In particular, isolated nucleic acid molecules are provided
 encoding the human TNFR-6.alpha. & -6.beta. proteins. TNFR-6.alpha. &
 -6.beta. polypeptides are also provided as are vectors, host cells and
 recombinant methods for producing the same. The invention further
 relates to screening methods for identifying agonists and antagonists of
 TNFR-6.alpha. & -6.beta. activity. Also provided are diagnostic methods
 for detecting immune system-related disorders and therapeutic methods
 for treating immune system-related disorders.

ACCESSION NUMBER: 2004:18362 USPATFULL
 TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta
 INVENTOR(S): Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ni, Jian, Germantown, MD, UNITED STATES
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Feng, Ping, Germantown, MD, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013664	A1	20040122
APPLICATION INFO.:	US 2003-418242	A1	20030418 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-935727, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373604P	20020419 (60)
	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)

US 1999-121774P	19990304 (60)
US 1997-35496P	19970114 (60)
US 1999-168235P	19991201 (60)
US 1999-146371P	19990802 (60)
US 1999-131964P	19990430 (60)
US 1999-131279P	19990427 (60)
US 1999-124092P	19990312 (60)
US 1999-121774P	19990304 (60)
US 1997-35496P	19970114 (60)
US 1997-35496P	19970114 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 40
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 23 Drawing Page(s)
 LINE COUNT: 13403

L11 ANSWER 13 OF 1550 USPATFULL on STN
 TI Novel nucleic acids and polypeptides
 AB The present invention provides novel nucleic acids, novel polypeptide
 sequences encoded by these nucleic acids and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:18355 USPATFULL
 TITLE: Novel nucleic acids and polypeptides
 INVENTOR(S): Tang, Y. Tom, San Jose, CA, UNITED STATES
 Asundi, Vinod, Foster City, CA, UNITED STATES
 Wehrman, Tom, Stanford, CA, UNITED STATES
 Yang, Yonghong, San Jose, CA, UNITED STATES
 Zhang, Jie, Campbell, CA, UNITED STATES
 Zhou, Ping, Cupertino, CA, UNITED STATES
 Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
 Goodrich, Ryle, Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013657	A1	20040122
APPLICATION INFO.:	US 2002-294006	A1	20021112 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US8964, filed on 20 Mar 2002, PENDING Continuation of Ser. No. US 2001-815925, filed on 22 Mar 2001, ABANDONED		

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085
 NUMBER OF CLAIMS: 27
 EXEMPLARY CLAIM: 1
 LINE COUNT: 10481
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 1550 USPATFULL on STN
 TI Interferon beta-like molecules
 AB The invention relates to a conjugate exhibiting interferon .beta. (IFNB)
 activity and comprising at least one first non-polypeptide moiety
 covalently attached to an IFNB polypeptide, the amino acid sequence of
 which differs from that of wildtype human IFNB in at least one
 introduced and at least one removed amino acid residue comprising an
 attachment group for said first non-polypeptide moiety. The first
 non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The
 conjugate finds particular use in therapy. The invention also relates to
 a glycosylated variant of a parent IFNB polypeptide comprising at least
 one in vivo glycosylation site, wherein an amino acid residue of said
 parent polypeptide located close to said glycosylation site has been

modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

ACCESSION NUMBER: 2004:18342 USPATFULL
TITLE: Interferon beta-like molecules
INVENTOR(S): Rasmussen, Poul Baad, Soeberg, DENMARK
Drustrup, Joern, Farum, DENMARK
Rasmussen, Grethe, Farum, DENMARK
Pedersen, Anders Hjelholt, Lyngby, DENMARK
Schambye, Hans Thalsgard, Frederiksberg C., DENMARK
Andersen, Kim Vilbour, Broenshoej, DENMARK
Bornaes, Claus, Hellerup, DENMARK
PATENT ASSIGNEE(S): Maxygen ApS (non-U.S. corporation)
Maxygen Holdings Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013644	A1	20040122
APPLICATION INFO.:	US 2003-609296	A1	20030627 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-84706, filed on 26 Feb 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-333	20010301
	DK 1999-1197	19990827
	DK 1999-1691	19991126
	DK 2000-194	20000207
	US 2001-272116P	20010227 (60)
	US 2001-343436P	20011221 (60)
	US 2001-302140P	20010629 (60)
	US 2001-316170P	20010830 (60)
	US 2002-357945P	20020219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CANDESCENT TECHNOLOGIES, 6320 SAN IGNACIO AVE., SAN JOSE, CA, 95119
NUMBER OF CLAIMS: 87
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5448

L11 ANSWER 15 OF 1550 USPATFULL on STN

TI **Albumin fusion** proteins
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: **Albumin fusion** proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004010134 A1 20040115
APPLICATION INFO.: US 2001-833245 A1 20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	25066	

L11 ANSWER 16 OF 1550 USPATFULL on STN

TI 53 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2004:13609 USPATFULL
TITLE: 53 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139 Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 27480

L11 ANSWER 17 OF 1550 USPATFULL on STN

TI Recombinant gene containing inverted repeat sequence and utilization thereof

AB The object of the present invention is to improve a method for introducing dsRNA in such a way that RNAi effect is sustained in mammalian (mainly mouse) cells for a long period of time. The present invention provides a recombinant gene which contains inverted repeats of a target gene which can be expressed in mammalian cells.

ACCESSION NUMBER: 2004:13607 USPATFULL
TITLE: Recombinant gene containing inverted repeat sequence and utilization thereof
INVENTOR(S): Katsuki, Motoya, Tokyo, JAPAN
Ishida, Mitsuyoshi, Tokyo, JAPAN
Kato, Minoru, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010130	A1	20040115
APPLICATION INFO.:	US 2003-296243	A1	20030616 (10)
	WO 2002-JP1554		20020221

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-46089	20010222
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENBLUM & BERNSTEIN, P.L.C., 1950 ROLAND CLARKE PLACE, RESTON, VA, 20191	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	3	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	876	

L11 ANSWER 18 OF 1550 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins

AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
TITLE: 7 Human ovarian and ovarian cancer associated proteins
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2004010121 A1 20040115
APPLICATION INFO.: US 2003-333900 A1 20030124 (10)
WO 2001-US8585 20010316
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 16023

L11 ANSWER 19 OF 1550 USPATFULL on STN

TI Methods of enhancing immune induction involving MDA-7
AB The present invention relates to compositions and methods for the
enhancing or inducing an immune response against an immunogenic molecule
by indirectly activating PKR. More specifically, immunotherapy is
improved by co-administering a MDA-7 polypeptide with an immunogenic
molecule against which an immune response is desired. Such
immunotherapies include cancer vaccines, and compositions thereof are
described.

ACCESSION NUMBER: 2004:13417 USPATFULL
TITLE: Methods of enhancing immune induction involving MDA-7
INVENTOR(S): Chada, Sunil, Missouri City, TX, UNITED STATES
Pataer, Abujiang, Houston, TX, UNITED STATES
Mhashilkar, Abner, Houston, TX, UNITED STATES
Ramesh, Rajagopal, Sugarland, TX, UNITED STATES
Roth, Jack, Houston, TX, UNITED STATES
Swisher, Steve, Fresno, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regent, The University of Texas System (U.S.
corporation)
Introgen Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009939	A1	20040115
APPLICATION INFO.:	US 2003-378590	A1	20030303 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404932P	20020821 (60)
	US 2002-370335P	20020405 (60)
	US 2002-361755P	20020305 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gina N. Shishima, Fulbright & Jaworski L.L.P., Suite
2400, 600 Congress Avenue, Austin, TX, 78701
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 73 Drawing Page(s)
LINE COUNT: 6371

L11 ANSWER 20 OF 1550 USPATFULL on STN

TI Macroaggregated **albumin**-polyethyleneimine (MAA-PEI)
lung-targeted delivery of respiratory syncytial virus DNA vaccines
AB The present invention provides a composition comprising: 1)
macroaggregated **albumin**, 2) a nucleic acid comprising a
nucleotide sequence encoding an RSV protein, and 3) polyethylamine
(PEI), wherein the MAA, PEI and nucleic acid form a complex. Also
provided by the present invention is a method of preventing respiratory
syncytial virus (RSV) infection in a subject comprising administering to
the subject an amount of a composition of this invention.

ACCESSION NUMBER: 2004:13381 USPATFULL

TITLE: Macroaggregated **albumin**-polyethyleneimine
(MAA-PEI) lung-targeted delivery of respiratory
syncytial virus DNA vaccines
INVENTOR(S): Tripp, Ralph A., Decatur, GA, UNITED STATES
Harcourt, Jennifer L., Lilburn, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009903	A1	20040115
APPLICATION INFO.:	US 2003-453219	A1	20030602 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-384586P	20020531 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NEEDLE & ROSENBERG, P.C., SUITE 1000, 999 PEACHTREE STREET, ATLANTA, GA, 30309-3915	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1297	

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55
ON 29 JAN 2004

L1 5340 S TIMP-1
L2 1 S CEREBUS PROTEIN
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4 41802 S INTERFERON ALPHA
L5 14602 S INTERFERON BETA
L6 258098 S ALBUMIN
L7 30354 S L6 AND FUSION
L8 214 S L7 AND L1
L9 0 S L7 AND L2
L10 636 S L7 AND L3
L11 1550 S L7 AND L4
L12 1361 S L7 AND L5
L13 0 S L6 AND L2

=> d l12 ti abs ibib 1-20

L12 ANSWER 1 OF 1361 MEDLINE on STN
TI An IFN-beta-**albumin fusion** protein that displays
improved pharmacokinetic and pharmacodynamic properties in nonhuman
primates.
AB The long half-life and stability of human serum **albumin** (HSA)
make it an attractive candidate for **fusion** to short-lived
therapeutic proteins. Albuferon (Human Genome Sciences [HGS], Inc.,
Rockville, MD) beta is a novel recombinant protein derived from a gene
fusion of interferon-beta (IFN-beta) and HSA.
In vitro, Albuferon beta displays antiviral and antiproliferative
activities and triggers the IFN-stimulated response element (ISRE) signal
transduction pathway. Array analysis of 5694 independent genes in
Daudi-treated cells revealed that Albuferon beta and IFN-beta induce the
expression of an identical set of 30 genes, including 9 previously not
identified. In rhesus monkeys administered a dose of 50 microg/kg
intravenously (i.v.) or subcutaneously (s.c.) or 300 microg/kg s.c.,
Albuferon beta demonstrated favorable pharmacokinetic properties.
Subcutaneous bioavailability was 87%, plasma clearance at 4.7-5.7 ml/h/kg

was approximately 140-fold lower than that of IFN-beta, and the terminal half-life was 36-40 h compared with 8 h for IFN-beta. Importantly, Albuferon beta induced sustained increases in serum neopterin levels and 2',5' mRNA expression. At a molar dose equivalent to one-half the dose of IFN-beta, Albuferon beta elicited comparable neopterin responses and significantly higher 2',5'-OAS mRNA levels in rhesus monkeys. The enhanced in vivo pharmacologic properties of IFN-beta when fused to serum albumin suggest a clinical opportunity for improved IFN-beta therapy.

ACCESSION NUMBER: 2003128795 MEDLINE
DOCUMENT NUMBER: 22526967 PubMed ID: 12639296
TITLE: An IFN-beta-**albumin fusion** protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.
AUTHOR: Sung Cynthia; Nardelli Bernardetta; LaFleur David W; Blatter Erich; Corcoran Marta; Olsen Henrik S; Birse Charles E; Pickeral Oxana K; Zhang Junli; Shah Devanshi; Moody Gordon; Gentz Solange; Beebe Lisa; Moore Paul A
CORPORATE SOURCE: Human Genome Sciences, Inc, Rockville, MD 20850, USA.
SOURCE: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (2003 Jan) 23 (1) 25-36.
Journal code: 9507088. ISSN: 1079-9907.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200309
ENTRY DATE: Entered STN: 20030320
Last Updated on STN: 20030928
Entered Medline: 20030926

L12 ANSWER 2 OF 1361 USPATFULL on STN

TI Methods and compositions for interferon therapy
AB Methods and pharmaceutical compositions for administering interferon therapy to tissues or organs having an epithelial cell layer are provided. A recombinant adenoviral vector encoding an interferon gene is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the transduction of the cells of the target tissues or organs by the vector. The methods and combinations are useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an adenoviral vector encoding alpha-interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 1,000 to 10,000 fold increase in interferon gene expression has been achieved by use of the combination of SYN3 with the recombinant adenoviral vector as compared to the use of the vector without SYN3.

ACCESSION NUMBER: 2004:19405 USPATFULL
TITLE: Methods and compositions for interferon therapy
INVENTOR(S): Engler, Heidrun, San Diego, CA, UNITED STATES
Nagabhushan, Tattanahalli L., Parsippany, NJ, UNITED STATES
Youngster, Stephen, Piscataway, NJ, UNITED STATES
PATENT ASSIGNEE(S): Canji, Inc., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014709	A1	20040122
APPLICATION INFO.:	US 2003-455215	A1	20030604 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-55863, filed on 22 Jan 2002, PENDING Continuation of Ser. No. US 1998-112074, filed on 8 Jul 1998, GRANTED, Pat. No. US		

6392069 Continuation-in-part of Ser. No. US
1997-889355, filed on 8 Jul 1997, PENDING
Continuation-in-part of Ser. No. US 1996-584077, filed
on 8 Jan 1996, GRANTED, Pat. No. US 5789244
Continuation-in-part of Ser. No. US 2003-454662, filed
on 3 Jun 2003, PENDING Continuation of Ser. No. US
2000-650359, filed on 28 Aug 2000, ABANDONED
Continuation of Ser. No. US 1997-779627, filed on 7 Jan
1997, GRANTED, Pat. No. US 6165779 Continuation-in-part
of Ser. No. US 1996-584077, filed on 8 Jan 1996,
GRANTED, Pat. No. US 5789244

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 2411

L12 ANSWER 3 OF 1361 USPATFULL on STN

TI Polynucleotide encoding a novel cysteine protease of the calpain
superfamily, Protease-42
AB The present invention provides novel polynucleotides encoding
Protease-42 polypeptides, fragments and homologues thereof. Also
provided are vectors, host cells, antibodies, and recombinant and
synthetic methods for producing said polypeptides. The invention further
relates to diagnostic and therapeutic methods for applying these novel
Protease-42 polypeptides to the diagnosis, treatment, and/or prevention
of various diseases and/or disorders related to these polypeptides. The
invention further relates to screening methods for identifying agonists
and antagonists of the polynucleotides and polypeptides of the present
invention.

ACCESSION NUMBER: 2004:18791 USPATFULL
TITLE: Polynucleotide encoding a novel cysteine protease of
the calpain superfamily, Protease-42
INVENTOR(S): Duclos, Franck, Washington Crossing, PA, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nayeem, Akbar, Newtown, PA, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014093	A1	20040122
APPLICATION INFO.:	US 2003-390585	A1	20030314 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364941P	20020314 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	19269	

L12 ANSWER 4 OF 1361 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically,
isolated nucleic acid molecules are provided encoding novel

polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:18737 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014039	A1	20040122
APPLICATION INFO.:	US 2002-158057	A1	20020531 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764890, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)

US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)

US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 26776

L12 ANSWER 5 OF 1361 USPATFULL on STN

TI Immunoreactive peptides from Epstein-Barr virus
AB Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also
disclosed are the use of these polypeptides for the production of
polypeptide-specific antibodies and the diagnosis and treatment of
EBV-associated disease.

ACCESSION NUMBER: 2004:18363 USPATFULL
TITLE: Immunoreactive peptides from Epstein-Barr virus
INVENTOR(S): Smith, Richard S., Salt Lake City, UT, UNITED STATES
Pearson, Gary R., Sedona, AZ, UNITED STATES
Parks, D. Elliot, Del Mar, CA, UNITED STATES
Varghese, Susan Pothen, Melrose, MA, UNITED STATES
PATENT ASSIGNEE(S): Ortho Diagnostic Systems, Inc. (U.S. corporation)
Georgetown University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013665	A1	20040122

APPLICATION INFO.: US 2003-442456 A1 20030521 (10)
 RELATED APPLN. INFO.: Division of Ser. No. US 1996-392934, filed on 28 Oct 1996, PENDING A 371 of International Ser. No. WO 1993-US8699, filed on 15 Sep 1993, PENDING
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: EMMA R. DAILEY, WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE 46TH FLOOR, PHILADELPHIA, PA, 19103
 NUMBER OF CLAIMS: 36
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 7 Drawing Page(s)
 LINE COUNT: 1490

L12 ANSWER 6 OF 1361 USPATFULL on STN

TI Tumor necrosis factor receptors 6 alpha & 6 beta
 AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6.alpha. & -6.beta. proteins. TNFR-6.alpha. & -6.beta. polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6.alpha. & -6.beta. activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

ACCESSION NUMBER: 2004:18362 USPATFULL
 TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta
 INVENTOR(S): Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ni, Jian, Germantown, MD, UNITED STATES
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Feng, Ping, Germantown, MD, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013664	A1	20040122
APPLICATION INFO.:	US 2003-418242	A1	20030418 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-935727, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373604P	20020419 (60)
	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)

US 1999-131279P 19990427 (60)
US 1999-124092P 19990312 (60)
US 1999-121774P 19990304 (60)
US 1997-35496P 19970114 (60)
US 1997-35496P 19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 13403

L12 ANSWER 7 OF 1361 USPATFULL on STN

TI **Interferon beta-like molecules**

AB The invention relates to a conjugate exhibiting **interferon . beta.** (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

ACCESSION NUMBER: 2004:18342 USPATFULL
TITLE: **Interferon beta-like molecules**
INVENTOR(S): Rasmussen, Poul Baad, Soeberg, DENMARK
Drusturp, Joern, Farum, DENMARK
Rasmussen, Grethe, Farum, DENMARK
Pedersen, Anders Hjelholt, Lyngby, DENMARK
Schambye, Hans Thalsgard, Frederiksberg C., DENMARK
Andersen, Kim Vilbour, Broenshoej, DENMARK
Bornaes, Claus, Hellerup, DENMARK
PATENT ASSIGNEE(S): Maxygen ApS (non-U.S. corporation)
Maxygen Holdings Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013644	A1	20040122
APPLICATION INFO.:	US 2003-609296	A1	20030627 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-84706, filed on 26 Feb 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-333	20010301
	DK 1999-1197	19990827
	DK 1999-1691	19991126
	DK 2000-194	20000207
	US 2001-272116P	20010227 (60)
	US 2001-343436P	20011221 (60)
	US 2001-302140P	20010629 (60)
	US 2001-316170P	20010830 (60)
	US 2002-357945P	20020219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CANDESCENT TECHNOLOGIES, 6320 SAN IGNACIO AVE., SAN

JOSE, CA, 95119
NUMBER OF CLAIMS: 87
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5448.

L12 ANSWER 8 OF 1361 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: **Albumin fusion** proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L12 ANSWER 9 OF 1361 USPATFULL on STN

TI 53 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2004:13609 USPATFULL
TITLE: 53 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES

Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139 Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	27480	

L12 ANSWER 10 OF 1361 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins
AB This invention relates to newly identified ovarian or ovarian cancer
related polynucleotides and the polypeptides encoded by these
polynucleotides herein collectively known as "ovarian cancer antigens",
and the use of such ovarian antigens for detecting disorders of the
reproductive system, particularly the presence of ovarian cancer and
ovarian cancer metastases. This invention relates to ovarian cancer
antigens as well as vectors, host cells, antibodies directed to ovarian
cancer antigens and the recombinant methods and synthetic methods for
producing the same. Also provided are diagnostic methods for detecting,
treating, preventing and/or prognosing disorders related to the ovary,
including ovarian cancer, and therapeutic methods for treating such
disorders. The invention further relates to screening methods for
identifying agonists and antagonists of ovarian cancer antigens of the
invention. The present invention further relates to inhibiting the
production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
TITLE: 7 Human ovarian and ovarian cancer associated proteins
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 16023

L12 ANSWER 11 OF 1361 USPATFULL on STN

TI Methods of enhancing immune induction involving MDA-7
AB The present invention relates to compositions and methods for the enhancing or inducing an immune response against an immunogenic molecule by indirectly activating PKR. More specifically, immunotherapy is improved by co-administering a MDA-7 polypeptide with an immunogenic molecule against which an immune response is desired. Such immunotherapies include cancer vaccines, and compositions thereof are described.

ACCESSION NUMBER: 2004:13417 USPATFULL
TITLE: Methods of enhancing immune induction involving MDA-7
INVENTOR(S): Chada, Sunil, Missouri City, TX, UNITED STATES
Pataer, Abujiang, Houston, TX, UNITED STATES
Mhashilkar, Abner, Houston, TX, UNITED STATES
Ramesh, Rajagopal, Sugarland, TX, UNITED STATES
Roth, Jack, Houston, TX, UNITED STATES
Swisher, Steve, Fresno, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regent, The University of Texas System (U.S. corporation)
Introgen Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009939	A1	20040115
APPLICATION INFO.:	US 2003-378590	A1	20030303 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-404932P	20020821 (60)
	US 2002-370335P	20020405 (60)
	US 2002-361755P	20020305 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gina N. Shishima, Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 73 Drawing Page(s)
LINE COUNT: 6371

L12 ANSWER 12 OF 1361 USPATFULL on STN

TI Polynucleotides encoding a novel intracellular chloride channel-related polypeptide
AB The present invention describes the novel human intracellular chloride ion channel-related protein HCLI and its encoding polynucleotide. Also described are expression vectors, host cells, antisense molecules, and antibodies associated with the HCLI polynucleotide and/or polypeptide of this invention. In addition, methods for treating, diagnosing, preventing, and screening for disorders or diseases associated with abnormal biological activity of HCLI are described, as are methods for screening for modulators, e.g., agonists or antagonists, of HCLI activity and/or function.

ACCESSION NUMBER: 2004:13393 USPATFULL
TITLE: Polynucleotides encoding a novel intracellular chloride channel-related polypeptide
INVENTOR(S): Chang, Han, Princeton Junction, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana M., Somerset, NJ, UNITED STATES

Rich, Adam, Yardley, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009915	A1	20040115
APPLICATION INFO.:	US 2003-384919	A1	20030306 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-362257P	20020306 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	7702	

L12 ANSWER 13 OF 1361 USPATFULL on STN

TI Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC1A, NARC 25, 86604 and 32222 molecules and uses therefor

AB The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, **fusion** proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

ACCESSION NUMBER: 2004:13033 USPATFULL

TITLE: Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC1A, NARC 25, 86604 and 32222 molecules and uses therefor

INVENTOR(S): Glucksmann, Maria A., Lexington, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Kapeller-Libermann, Rosanna, Chestnut Hill, MA, UNITED STATES

Meyers, Rachel E., Newton, MA, UNITED STATES
Chiang, Lillian Wei-Ming, Edison, NJ, UNITED STATES
Hunter, John Joseph, Somerville, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009553	A1	20040115
APPLICATION INFO.:	US 2003-426776	A1	20030430 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-229662, filed		

on 28 Aug 2002, PENDING Division of Ser. No. US
 2001-795691, filed on 28 Feb 2001, GRANTED, Pat. No. US
 6465230 Continuation-in-part of Ser. No. US
 2002-105992, filed on 25 Mar 2002, PENDING Continuation
 of Ser. No. US 1999-406045, filed on 27 Sep 1999,
 GRANTED, Pat. No. US 6451994 Continuation-in-part of
 Ser. No. US 2002-314881, filed on 9 Dec 2002, PENDING
 Continuation of Ser. No. US 2001-773426, filed on 31
 Jan 2001, GRANTED, Pat. No. US 6534302
 Continuation-in-part of Ser. No. US 2000-495823, filed
 on 31 Jan 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-692785, filed on 20 Oct 2000, PENDING
 Continuation-in-part of Ser. No. US 2002-284014, filed
 on 30 Oct 2002, PENDING Continuation-in-part of Ser.
 No. US 2002-284059, filed on 30 Oct 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-185517P	20000228 (60)
	US 1999-161188P	19991022 (60)
	US 2001-335003P	20011031 (60)
	US 2001-335037P	20011031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	24534	

L12 ANSWER 14 OF 1361 USPATFULL on STN

TI Export and modification of (poly)peptides in the lantibiotic way
 AB The invention includes a method for harvesting a polypeptide produced by
 a host cell, wherein the polypeptide has not undergone intra-cellular
 post-translational modification, such as dehydration of a serine or a
 threonine, and/or thioether bridge formation. The invention also
 includes a method for producing thioether containing peptides and
 dehydroalanine/dehydrobutyrine-containing peptides, wherein
 extracellularly thioether rings may be formed.

ACCESSION NUMBER: 2004:13030 USPATFULL
 TITLE: Export and modification of (poly)peptides in the
 lantibiotic way
 INVENTOR(S): Moll, Gert Nikolaas, Groningen, NETHERLANDS
 Leenhouts, Cornelis Johannes, Haren, NETHERLANDS

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009550	A1	20040115
APPLICATION INFO.:	US 2003-360101	A1	20030207 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2002-77060	20020524
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	3337	

L12 ANSWER 15 OF 1361 USPATFULL on STN

TI Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839,

49937, 49931 and 49933 molecules and uses therefor
AB The invention provides isolated nucleic acids molecules, designated
25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937,
49931 and 49933 nucleic acid molecules. The invention also provides
antisense nucleic acid molecules, recombinant expression vectors
containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816,
16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into
which the expression vectors have been introduced, and nonhuman
transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692,
46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or
disrupted. The invention still further provides isolated 25869, 25934,
26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933
proteins, fusion proteins, antigenic peptides and anti-25869,
25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or
49933 antibodies. Diagnostic and therapeutic methods utilizing
compositions of the invention are also provided.

ACCESSION NUMBER: 2004:12981 USPATFULL
TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508,
16816, 16839, 49937, 49931 and 49933 molecules and uses
therefor
INVENTOR(S): Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED
STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009501	A1	20040115
APPLICATION INFO.:	US 2003-377072	A1	20030227 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215370P	20000629 (60)
	US 2000-187455P	20000307 (60)
	US 2000-199801P	20000426 (60)
	US 2000-205508P	20000519 (60)
	US 2000-213688P	20000623 (60)
	US 2000-218675P	20000717 (60)
	US 2000-250932P	20001130 (60)
	US 2000-226504P	20000821 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139
NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1
LINE COUNT: 16123

L12 ANSWER 16 OF 1361 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L12 ANSWER 17 OF 1361 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)

US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)

US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L12 ANSWER 18 OF 1361 USPATFULL on STN

TI Compositions, kits, and methods for identification, assessment,
prevention, and therapy of human prostate cancer
AB The invention relates to compositions, kits, and methods for diagnosing,
staging, prognosing, monitoring and treating human prostate cancers. A
variety of marker genes are provided, wherein changes in the levels of
expression of one or more of the marker genes is correlated with the
presence of prostate cancer.

ACCESSION NUMBER: 2004:12961 USPATFULL
TITLE: Compositions, kits, and methods for identification,
assessment, prevention, and therapy of human prostate
cancer
INVENTOR(S): Schlegel, Robert, Auburndale, MA, UNITED STATES
Endege, Wilson O., Norwood, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., Cambridge, MA (U.S.
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009481	A1	20040115	
APPLICATION INFO.:	US 2002-166883	A1	20020611	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-297285P	20010611 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	15572	

L12 ANSWER 19 OF 1361 USPATFULL on STN

TI Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases

AB Methods of diagnosing or monitoring an autoimmune or chronic inflammatory disease, particularly SLE in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring chronic inflammatory disease, particularly SLE infection and kits or systems containing the same are also described.

ACCESSION NUMBER: 2004:12959 USPATFULL

TITLE: Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases

INVENTOR(S): Wohlgemuth, Jay, Palo Alto, CA, UNITED STATES
Fry, Kirk, Palo Alto, CA, UNITED STATES
Woodward, Robert, Pleasanton, CA, UNITED STATES
Ly, Ngoc, San Bruno, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009479	A1	20040115
APPLICATION INFO.:	US 2002-131827	A1	20020424 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-6290, filed on 22 Oct 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296764P	20010608 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Michael R. Ward, Morrison & Foerster LLP, 425 Market Street, San Francisco, CA, 94105-2482	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	19677	

L12 ANSWER 20 OF 1361 USPATFULL on STN

TI Multimeric binding complexes

AB The invention provides multimeric receptor-binding complexes, including chemokine tetramers, useful for recognizing and binding receptors bound to the surface of a wide variety of cells. The binding complexes are useful for identifying and isolating cells according to their specific receptors, screening for cells having a specific receptor or constellation of receptors, and introducing exogenous molecules (e.g., nucleic acids and toxins) into cells. Methods of producing the complexes and other uses are also described.

ACCESSION NUMBER: 2004:12631 USPATFULL

TITLE: Multimeric binding complexes

INVENTOR(S): Altman, John D., Decatur, GA, UNITED STATES
Ravkov, Eugene, Tucker, GA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2004009149	A1	20040115	
APPLICATION INFO.:	US 2003-376887	A1	20030227	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-360724P	20020227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	1909	

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55 ON 29 JAN 2004

L1	5340 S	TIMP-1
L2	1 S	CEREBUS PROTEIN
L3	10853 S	BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4	41802 S	INTERFERON ALPHA
L5	14602 S	INTERFERON BETA
L6	258098 S	ALBUMIN
L7	30354 S	L6 AND FUSION
L8	214 S	L7 AND L1
L9	0 S	L7 AND L2
L10	636 S	L7 AND L3
L11	1550 S	L7 AND L4
L12	1361 S	L7 AND L5
L13	0 S	L6 AND L2

=> s albumin fusion protein () interferon alpha

L14 5 ALBUMIN FUSION PROTEIN (W) INTERFERON ALPHA

=> d l14 ti abs ibib tot

L14 ANSWER 1 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER:	2004:13611	USPATFULL
TITLE:	Albumin fusion proteins	
INVENTOR(S):	Rosen, Craig A., Laytonsville, MD, UNITED STATES Haseltine, William A., Washington, DC, UNITED STATES	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	25066	

L14 ANSWER 2 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL
 TITLE: Albumin fusion proteins
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	15415	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or

ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55
ON 29 JAN 2004

L1 5340 S TIMP-1
L2 1 S CEREBUS PROTEIN
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4 41802 S INTERFERON ALPHA
L5 14602 S INTERFERON BETA
L6 258098 S ALBUMIN
L7 30354 S L6 AND FUSION
L8 214 S L7 AND L1
L9 0 S L7 AND L2

L10 636 S L7 AND L3
L11 1550 S L7 AND L4
L12 1361 S L7 AND L5
L13 0 S L6 AND L2
L14 5 S ALBUMIN FUSION PROTEIN () INTERFERON ALPHA

=> s albumin fusion protein () interferon beta
L15 5 ALBUMIN FUSION PROTEIN (W) INTERFERON BETA

=> d l15 ti abs ibib tot

L15 ANSWER 1 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L15 ANSWER 2 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:312278 USPATFULL
TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 3 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 4 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 59

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 20 Drawing Page(s)

LINE COUNT: 13208

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L15 ANSWER 5 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703

APPLICATION INFO.: US 2001-833041 A1 20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55
ON 29 JAN 2004

L1 5340 S TIMP-1
L2 1 S CEREBUS PROTEIN
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4 41802 S INTERFERON ALPHA
L5 14602 S INTERFERON BETA
L6 258098 S ALBUMIN
L7 30354 S L6 AND FUSION
L8 214 S L7 AND L1
L9 0 S L7 AND L2
L10 636 S L7 AND L3
L11 1550 S L7 AND L4
L12 1361 S L7 AND L5
L13 0 S L6 AND L2
L14 5 S ALBUMIN FUSION PROTEIN () INTERFERON ALPHA
L15 5 S ALBUMIN FUSION PROTEIN () INTERFERON BETA

=> s albumin fusion protein () BDNF

L16 1 ALBUMIN FUSION PROTEIN (W) BDNF

=> d l16 ti abs ibib tot

L16 ANSWER 1 OF 1 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	15415	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> s albumin fusion protein () TIMP-1
5 FILES SEARCHED...
L17 5 ALBUMIN FUSION PROTEIN (W) TIMP-1

=> d l17 ti abs ibib tot

L17 ANSWER 1 OF 5 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	25066	

L17 ANSWER 2 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)

LINE COUNT: 15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023

APPLICATION INFO.: US 2001-832501 A1 20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	14339	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	13208	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 5 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and

methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	15235	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:21:39 ON 29 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 18:21:55
ON 29 JAN 2004

L1 5340 S TIMP-1
L2 1 S CEREBUS PROTEIN
L3 10853 S BRAIN DERIVED NEUROTROPHIC FACTOR OR BDNF
L4 41802 S INTERFERON ALPHA
L5 14602 S INTERFERON BETA
L6 258098 S ALBUMIN
L7 30354 S L6 AND FUSION
L8 214 S L7 AND L1
L9 0 S L7 AND L2
L10 636 S L7 AND L3
L11 1550 S L7 AND L4
L12 1361 S L7 AND L5
L13 0 S L6 AND L2
L14 5 S ALBUMIN FUSION PROTEIN () INTERFERON ALPHA
L15 5 S ALBUMIN FUSION PROTEIN () INTERFERON BETA
L16 1 S ALBUMIN FUSION PROTEIN () BDNF
L17 5 S ALBUMIN FUSION PROTEIN () TIMP-1

=> s ablumin fusion protein

L18 0 ABLUMIN FUSION PROTEIN

=> s albumin fusion protein

L19 2840 ALBUMIN FUSION PROTEIN

=> d 119 ti abs ibib 1-30

L19 ANSWER 1 OF 2840 MEDLINE on STN

TI An IFN-beta-**albumin fusion protein** that

displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.

AB The long half-life and stability of human serum albumin (HSA) make it an attractive candidate for fusion to short-lived therapeutic proteins. Albuferon (Human Genome Sciences [HGS], Inc., Rockville, MD) beta is a novel recombinant protein derived from a gene fusion of interferon-beta (IFN-beta) and HSA. In vitro, Albuferon beta displays antiviral and antiproliferative activities and triggers the IFN-stimulated response element (ISRE) signal transduction pathway. Array analysis of 5694 independent genes in Daudi-treated cells revealed that Albuferon beta and IFN-beta induce the expression of an identical set of 30 genes, including 9 previously not identified. In rhesus monkeys administered a dose of 50 microg/kg intravenously (i.v.) or subcutaneously (s.c.) or 300 microg/kg s.c., Albuferon beta demonstrated favorable pharmacokinetic properties. Subcutaneous bioavailability was 87%, plasma clearance at 4.7-5.7 ml/h/kg was approximately 140-fold lower than that of IFN-beta, and the terminal half-life was 36-40 h compared with 8 h for IFN-beta. Importantly, Albuferon beta induced sustained increases in serum neopterin levels and 2',5' mRNA expression. At a molar dose equivalent to one-half the dose of IFN-beta, Albuferon beta elicited comparable neopterin responses and significantly higher 2',5'-OAS mRNA levels in rhesus monkeys. The enhanced in vivo pharmacologic properties of IFN-beta when fused to serum albumin suggest a clinical opportunity for improved IFN-beta therapy.

ACCESSION NUMBER: 2003128795 MEDLINE

DOCUMENT NUMBER: 22526967 PubMed ID: 12639296

TITLE: An IFN-beta-**albumin fusion**

protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates.

AUTHOR: Sung Cynthia; Nardelli Bernardetta; LaFleur David W; Blatter Erich; Corcoran Marta; Olsen Henrik S; Birse Charles E; Pickeral Oxana K; Zhang Junli; Shah Devanshi; Moody Gordon; Gentz Solange; Beebe Lisa; Moore Paul A

CORPORATE SOURCE: Human Genome Sciences, Inc, Rockville, MD 20850, USA.

SOURCE: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, (2003 Jan) 23 (1) 25-36.

Journal code: 9507088. ISSN: 1079-9907.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200309

ENTRY DATE: Entered STN: 20030320

Last Updated on STN: 20030928

Entered Medline: 20030926

L19 ANSWER 2 OF 2840 MEDLINE on STN

TI Pharmaceutical strategies utilizing recombinant human serum albumin.

AB Gene manipulation techniques open up the possibility of making recombinant human serum albumin (rHSA) or mutants with desirable therapeutic properties and for protein fusion products. rHSA can serve as a carrier in synthetic heme protein, thus reversibly carrying oxygen. Myristoylation of insulin results in a prolonged half-life because of self aggregation and increased albumin binding. Preferential albumin uptake by tumor cells serves as the basis for albumin-anticancer drug conjugate formulation. Furthermore, drug targeting can be achieved by incorporating drugs into albumin microspheres whereas liver targeting can be achieved by conjugating drug with galactosylated or mannosylated albumin. Microspheres and nanoparticles of different sizes can, with or without drugs and/or radioisotopes, be used for drug delivery or diagnostic purposes. In vivo implantation of **albumin fusion**

protein expressing cells encapsulated in HSA-alginate coated beads showed promising results compared to organoids in rats. Chimeric peptide strategy with cationized albumin as the transport can deliver drugs via receptor mediated transcytosis through the blood brain barrier. Gene bearing, albumin microbubbles containing ultrasound contrast agents can non-invasively deliver gene after destruction by ultrasound. Various site-directed mutants of HSA can be tailor made depending on the application required.

ACCESSION NUMBER: 2002326620 MEDLINE
DOCUMENT NUMBER: 22064084 PubMed ID: 12069157
TITLE: Pharmaceutical strategies utilizing recombinant human serum albumin.
AUTHOR: Chuang Victor Tuan Giam; Kragh-Hansen Ulrich; Otagiri Masaki
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Kumamoto University, Japan.
SOURCE: PHARMACEUTICAL RESEARCH, (2002 May) 19 (5) 569-77. Ref: 91
Journal code: 8406521. ISSN: 0724-8741.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200302
ENTRY DATE: Entered STN: 20020619
Last Updated on STN: 20030214
Entered Medline: 20030213

L19 ANSWER 3 OF 2840 MEDLINE on STN

TI A barbourin-**albumin fusion protein** that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro.

AB Barbourin is a 73 amino acid venom protein that inhibits platelet aggregation. Recombinant barbourin (BARH6), rabbit serum albumin (RSAH6), and a barbourin-RSA fusion protein (barbourin-linker-albumin; BLAH6) were secreted from Pichia pastoris yeast, and purified by nickel-chelate affinity chromatography via their C-terminal hexahistidine (H6) tags. BARH6 and BLAH6 did not differ in their IC50s for inhibition of platelet aggregation using either human platelets stimulated with thrombin or ADP, or rabbit platelets stimulated with ADP. BARH6 and BLAH6 were also effective in inhibiting platelet aggregation in whole blood, and formed complexes with platelet integrin α IIb β 3. The terminal catabolic half-life of BLAH6 approached that of RSAH6 [3.4 +/- 0.2 versus 4.0 +/- 0.1 days (n = 4 +/- SD)], but was substantially increased relative to that of BARH6 [0.15 +/- 0.03 days (n = 3 +/- SD)]. Our results suggest that fusion to albumin slows the clearance of barbourin in vivo, while preserving its ability to inhibit platelet aggregation.

ACCESSION NUMBER: 2001535476 MEDLINE
DOCUMENT NUMBER: 21467016 PubMed ID: 11583325
TITLE: A barbourin-**albumin fusion protein** that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro.
AUTHOR: Marques J A; George J K; Smith I J; Bhakta V; Sheffield W P
CORPORATE SOURCE: Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
SOURCE: THROMBOSIS AND HAEMOSTASIS, (2001 Sep) 86 (3) 902-8.
Journal code: 7608063. ISSN: 0340-6245.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200204
ENTRY DATE: Entered STN: 20011004

Last Updated on STN: 20020409
Entered Medline: 20020408

L19 ANSWER 4 OF 2840 MEDLINE on STN

TI Prolonged in vivo anticoagulant activity of a hirudin-**albumin fusion protein** secreted from *Pichia pastoris*.

AB Hirudin is a small, proteinaceous thrombin inhibitor that clears rapidly from the circulation. A hexahistidine-tagged hirudin-rabbit serum albumin (RSA) fusion protein, HLAH6, was characterized following secretion from *Pichia pastoris*. HLAH6 bound to immobilized nickel, anti-RSA, and anti-hexahistidine antibodies, and contained the expected (ITYTD) N-terminus. Its spectrometric mass was 74,490 (versus the theoretical mass of 74,410 and sodium dodecyl sulfate-polyacrylamide gel electrophoresis mobility of 84 kDa). The terminal catabolic half-life in rabbits of HLAH6, recombinant *Pichia*-derived His-tagged RSA, or plasma-derived RSA did not differ. Injection of 2 mg/kg HLAH6 into rabbits raised the activated partial thromboplastin time (aPTT) above initial values for 4-24 h, while the equimolar dose of unfused hirudin was without significant effect. A higher dose of HLAH6 (3 mg/kg functional HLAH6, equivalent to 37.6 thrombin-inhibitory units/g) raised the aPTT by 2.0- to 2.5-fold; the elevation persisted for > 48 h. Importantly, both HLAH6 and unfused hirudin inhibited clot-bound thrombin. Our results suggest that HLAH6 exhibits not only delayed clearance, but also prolonged biological activity in vivo compared with unfused hirudin.

ACCESSION NUMBER: 2001506683 MEDLINE

DOCUMENT NUMBER: 21439005 PubMed ID: 11555696

TITLE: Prolonged in vivo anticoagulant activity of a hirudin-**albumin fusion protein** secreted from *Pichia pastoris*.

AUTHOR: Sheffield W P; Smith I J; Syed S; Bhakta V

CORPORATE SOURCE: Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ont., Canada.. sheffiel@mcmaster.ca

SOURCE: BLOOD COAGULATION AND FIBRINOLYSIS, (2001 Sep) 12 (6) 433-43.

Journal code: 9102551. ISSN: 0957-5235.

PUB. COUNTRY: England: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200112

ENTRY DATE: Entered STN: 20010917

Last Updated on STN: 20020122

Entered Medline: 20011204

L19 ANSWER 5 OF 2840 USPATFULL on STN

TI Tumor necrosis factor receptors 6 alpha & 6 beta

AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6.alpha. & -6.beta. proteins. TNFR-6.alpha. & -6.beta. polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6.alpha. & -6.beta. activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

ACCESSION NUMBER: 2004:18362 USPATFULL

TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta

INVENTOR(S): Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL

Yu, Guo-Liang, Berkeley, CA, UNITED STATES

Ni, Jian, Germantown, MD, UNITED STATES

Ebner, Reinhard, Gaithersburg, MD, UNITED STATES

Feng, Ping, Germantown, MD, UNITED STATES

Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004013664	A1	20040122
APPLICATION INFO.:	US 2003-418242	A1	20030418 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-935727, filed on 24 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373604P	20020419 (60)
	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131279P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)
	US 1997-35496P	19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 13403

L19 ANSWER 6 OF 2840 USPATFULL on STN

TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004010134 A1 20040115
APPLICATION INFO.: US 2001-833245 A1 20010412 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L19 ANSWER 7 OF 2840 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2003219875 A1 20031127
APPLICATION INFO.: US 2001-833118 A1 20010412 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 8 OF 2840 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using

these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 2840 USPATFULL on STN

TI Binding polypeptides for B lymphocyte stimulator protein (BLyS)
AB Binding polypeptides comprising specific amino acid sequences are disclosed that bind B Lymphocyte Stimulator (BLyS) protein or BLyS-like polypeptides. The binding polypeptides can be used in methods of the invention for detecting or isolating BLyS protein or BLyS-like polypeptides in solutions or mixtures, such as blood, tissue samples, or conditioned media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:276718 USPATFULL
TITLE: Binding polypeptides for B lymphocyte stimulator protein (BLyS)
INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES
Potter, M. Daniel, Acton, MA, UNITED STATES
Potter, Marilou, Acton, MA, UNITED STATES LR
Fleming, Tony J., Waltham, MA, UNITED STATES
Ladner, Robert Charles, Ijamsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003194743	A1	20031016
APPLICATION INFO.:	US 2001-932322	A1	20010817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226489P	20000818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: Leon R. Yankwich, Esq., YANKWICH & ASSOCIATES, 201
Broadway, Cambridge, MA, 02139
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
LINE COUNT: 6942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 10 OF 2840 USPATFULL on STN

TI Neutrokin- α and neutrokin- α splice variant
AB The present invention relates to nucleic acid molecules encoding
Neutrokin- α and/or Neutrokin- α SV polypeptides, including
soluble forms of the extracellular domain. Neutrokin- α and/or
Neutrokin- α SV polypeptides are also provided as are vectors, host
cells and recombinant methods for producing the same. The invention
further relates to antibodies or portions thereof that specifically bind
Neutrokin- α and/or Neutrokin- α SV and diagnostic and
therapeutic methods using these antibodies. Also provided are diagnostic
methods for detecting immune system-related disorders and therapeutic
methods for treating immune system-related disorders using the
compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250423 USPATFULL
TITLE: Neutrokin- α and neutrokin- α splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Laird, Michael, Germantown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED
STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed on 8 Jun 2000, GRANTED, Pat. No. US 6403770 Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998, PENDING Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on		

12 Jan 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-329508P	20011017 (60)
	US 2001-329747P	20011018 (60)
	US 2001-330835P	20011031 (60)
	US 2001-331478P	20011116 (60)
	US 2001-336726P	20011207 (60)
	US 2002-368548P	20020401 (60)
	US 2000-225628P	20000815 (60)
	US 2000-227008P	20000823 (60)
	US 2000-234338P	20000922 (60)
	US 2000-240806P	20001017 (60)
	US 2000-250020P	20001130 (60)
	US 2001-276248P	20010316 (60)
	US 2001-293499P	20010525 (60)
	US 2001-296122P	20010607 (60)
	US 2001-304809P	20010713 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1997-36100P	19970114 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Page(s)	
LINE COUNT:	18884	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L19 ANSWER 11 OF 2840 USPATFULL on STN
TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 12 OF 2840 USPATFULL on STN

TI Death domain containing receptors

AB The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:243794 USPATFULL
TITLE: Death domain containing receptors
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte, BRAZIL
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170203	A1	20030911
APPLICATION INFO.:	US 2002-189189	A1	20020705 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-557908, filed		

on 21 Apr 2000, PENDING Continuation-in-part of Ser.
No. US 1997-815469, filed on 11 Mar 1997, GRANTED, Pat.
No. US 6153402

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-314314P	20010824 (60)
	US 2001-303155P	20010706 (60)
	US 1999-136741P	19990528 (60)
	US 1999-130488P	19990422 (60)
	US 1997-37341P	19970206 (60)
	US 1996-28711P	19961017 (60)
	US 1996-13285P	19960312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	83	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	9858	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L19 ANSWER 13 OF 2840 USPATFULL on STN

TI Chemokine beta-1 fusion proteins

AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ck.beta.-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-.gamma., and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:206834 USPATFULL
TITLE: Chemokine beta-1 fusion proteins
INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143191	A1	20030731
APPLICATION INFO.:	US 2002-153604	A1	20020524 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293212P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	15446	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L19 ANSWER 14 OF 2840 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also

encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 15 OF 2840 USPATFULL on STN

TI Binding polypeptides and methods based thereon
AB Binding polypeptides that specifically bind BLYS protein or BLYS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLYS or BLYS receptor expression or inappropriate function of BLYS or BLYS receptor, comprising BLYS binding polypeptides or fragments or variants thereof, that specifically bind to BLYS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLYS or BLYS receptor expression or inappropriate BLYS function or BLYS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLYS binding polypeptides or fragments or variants thereof, that specifically bind to BLYS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:133480 USPATFULL
TITLE: Binding polypeptides and methods based thereon
INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES
Potter, M. Daniel, UNITED STATES
Potter, Marilou, Acton, MA, UNITED STATES LR
Fleming, Tony J., Waltham, MA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091565	A1	20030515
APPLICATION INFO.:	US 2001-932613	A1	20010817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226700P	20000818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Leon R. Yankwich, Esq., Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	71	
EXEMPLARY CLAIM:	1	
LINE COUNT:	11834	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L19 ANSWER 16 OF 2840 USPATFULL on STN

TI Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury

AB KAL protein is identified as the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:102360 USPATFULL

TITLE: Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury

INVENTOR(S): Petit, Christine, Le Plessis-Robinson, FRANCE
Soussi-Yanticostas, Nadia, Paris, FRANCE
Hardelin, Jean-Pierre, Paris, FRANCE
Sarailh, Catherine, Marseille, FRANCE
Rougon, Genevieve, Marseille, FRANCE
Legouis, Renaud, Strasbourg, FRANCE
Ardouin, Olivier, Issy-les-Mou-lineaux, FRANCE
Mazie, Jean-Claude, Asnieres, FRANCE

PATENT ASSIGNEE(S): Institut Pasteur, Paris, FRANCE (non-U.S. corporation)
Centre National de la Recherche Scientifique, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6548475	B1	20030415
APPLICATION INFO.:	US 2000-576967		20000524 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-761136, filed on 6 Dec 1996, now patented, Pat. No. US 6121231		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ulm, John		
ASSISTANT EXAMINER:	Chernyshev, Olga N.		
LEGAL REPRESENTATIVE:	Obлон, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	1338		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L19 ANSWER 17 OF 2840 USPATFULL on STN

TI Serum albumin binding moieties

AB Compositions comprising non-naturally occurring serum albumin binding moieties are described, together with methods of use thereof, e.g., for detecting or isolating serum albumin molecules in a solution, for blood circulation imaging, and for linking therapeutics or other molecules to albumin. Preferred serum albumin binding peptides having a high affinity

for human serum albumin are particularly disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100284 USPATFULL
TITLE: Serum albumin binding moieties
INVENTOR(S): Sato, Aaron K., Somerville, MA, UNITED STATES
Ley, Arthur C., Newton, MA, UNITED STATES
Cohen, Edward H., Belmont, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069395	A1	20030410
APPLICATION INFO.:	US 2002-94401	A1	20020308 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-331352P	20010309 (60)
	US 2001-292975P	20010523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LEON R. YANKWICH, YANKWICH & ASSOCIATES, 201 BROADWAY, CAMBRIDGE, MA, 02139	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	4384	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 18 OF 2840 USPATFULL on STN

TI Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury

AB KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:86793 USPATFULL
TITLE: Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
INVENTOR(S): Petit, Christine, Le Plessis-Robinson, FRANCE
Soussi-Yanticostas, Nadia, Paris, FRANCE
Hardelin, Jean-Pierre, Paris, FRANCE
Sarailh, Catherine, Marseille, FRANCE
Rougon, Genevieve, Marseille, FRANCE
Legouis, Renaud, Strasbourg, FRANCE
Ardouin, Olivier, Issy-les-Mou-lineaux, FRANCE
Mazie, Jean-Claude, Asnieres, FRANCE
PATENT ASSIGNEE(S): INSTITUT PASTEUR, PARIS CEDEX, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003060401	A1	20030327
APPLICATION INFO.:	US 2002-219541	A1	20020816 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-576967, filed on 24 May 2000, PENDING Division of Ser. No. US 1996-761136, filed on 6 Dec 1996, GRANTED, Pat. No. US 6121231		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940
DUKE STREET, ALEXANDRIA, VA, 22314
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 1363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 19 OF 2840 USPATFULL on STN

TI Tumor necrosis factor receptors 6alpha & 6beta
AB The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6.alpha. & -6.beta. proteins. TNFR-6.alpha. & -6.beta. polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6.alpha. & -6.beta. activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:272468 USPATFULL
TITLE: Tumor necrosis factor receptors 6alpha & 6beta
INVENTOR(S): Gentz, Reiner L., Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150583	A1	20021017
APPLICATION INFO.:	US 2001-935727	A1	20010824 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING Continuation-in-part of Ser. No. US 2000-518931, filed on 3 Mar 2000, PENDING Continuation-in-part of Ser. No. US 1998-6352, filed on 13 Jan 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-303224P	20010706 (60)
	US 2000-252131P	20001121 (60)
	US 2000-227598P	20000825 (60)
	US 1999-168235P	19991201 (60)
	US 1999-146371P	19990802 (60)
	US 1999-131964P	19990430 (60)
	US 1999-131270P	19990427 (60)
	US 1999-124092P	19990312 (60)
	US 1999-121774P	19990304 (60)
	US 1997-35496P	19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 12989
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 20 OF 2840 USPATFULL on STN

TI Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury

AB KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:228307 USPATFULL

TITLE: Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury

INVENTOR(S): Petit, Christine, Le Plessis-Robinson, FRANCE
Soussi-Yanicostas, Nadia, Paris, FRANCE
Hardelin, Jean-Pierre, Paris, FRANCE
Sarailh, Catherine, Marseille, FRANCE
Rougon, Genevieve, Marseille, FRANCE
Legouis, Renaud, Strasbourg, FRANCE
Ardouin, Olivier, Issy Les Moulineaux, FRANCE
Mazie, Jean-Claude, Asnieres, FRANCE

PATENT ASSIGNEE(S): INSTITUT PASTEUR, Paris Cedex, FRANCE, 75724 (non-U.S. individual)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002123467	A1	20020905
APPLICATION INFO.:	US 2002-119714	A1	20020411 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-319236, filed on 2 Sep 1999, PENDING A 371 of International Ser. No. WO 1997-EP6806, filed on 5 Dec 1997, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Page(s)		
LINE COUNT:	1904		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 21 OF 2840 USPATFULL on STN

TI Hyaluronan receptor protein

AB The present invention relates to a novel hyaluronan receptor protein involved in cell locomotion or motility and in cell proliferation and transformation and to DNA sequences encoding this protein. The protein is designated Receptor for Hyaluronic Acid Mediated Motility or RHAMM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:194945 USPATFULL

TITLE: Hyaluronan receptor protein

INVENTOR(S): Turley, Eva Ann, #5 - 375 Wellington Crescent, Winnipeg, Manitoba, CANADA L2M 0A1
Zhang, Shuwen, 143 Branson Crescent, Winnipeg, Manitoba, CANADA R2P 9N9
Entwistle, Jocelyn, 380 Linden Wood Drive East, Winnipeg, Manitoba, CANADA R3P 2H1

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 6429291 B1 20020806
APPLICATION INFO.: US 1995-477831 19950607 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-20740	19941014
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kemmerer, Elizabeth	
LEGAL REPRESENTATIVE:	Fish & Neave, Pierri, Margaret A., Mayrand, Shawn-Marie	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	123 Drawing Figure(s); 70 Drawing Page(s)	
LINE COUNT:	3544	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 22 OF 2840 USPATFULL on STN

TI Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuromal and neural injury

AB KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:125008 USPATFULL

TITLE: Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuromal and neural injury

INVENTOR(S): Petit, Christine, Le Plessis-Robinson, France
Soussi-Yanticostas, Nadia, Paris, France
Hardelin, Jean-Pierre, Paris, France
Sarailh, Catherine, Marseilles, France
Rougon, Genevieve, Marseilles, France
Legouis, Renaud, Strasbourg, France
Ardouin, Olivier, Issy-les-Mou-lineaux, France
Mazie, Jean-Claude, Asnieres, France

PATENT ASSIGNEE(S): Institut Pasteur, Paris, France (non-U.S. corporation)
Centre Nationale de la Recherche Scientifique, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121231		20000919
APPLICATION INFO.:	US 1996-761136		19961206 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Duffy, Patricia A.		
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 17 Drawing Page(s)		
LINE COUNT:	1334		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 23 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68074 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68074 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.

(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-810996 [76]

DESCRIPTION: Human therapeutic protein #4.

L19 ANSWER 24 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68075 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68075 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.

(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Human therapeutic protein #5.

L19 ANSWER 25 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68073 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68073 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.
(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-810996 [76]

DESCRIPTION: Human therapeutic protein #3.

L19 ANSWER 26 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68072 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68072 protein DGENE

TITLE: New **albumin fusion protein** for
diagnosing, preventing or treating diseases (e.g. HIV,
cancer, atherosclerosis or stroke) comprises a therapeutic
protein (e.g. cathepsin K or vascular endothelial growth
factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412
US 2000-199384P 20000425
US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-810996 [76]

DESCRIPTION: Human therapeutic protein #2.

L19 ANSWER 27 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing,
preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or
stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular
endothelial growth factor) and an albumin.

AN ADD68005 peptide DGENE

AB The present invention relates to albumin fusion proteins comprising any
of the therapeutic proteins listed in the specification, or their
fragments or variants, and an albumin protein or its fragments or
variants. The invention also discloses pharmaceutical compositions
comprising the albumin fusion proteins, a kit comprising the albumin
fusion proteins, and methods for treating a disease or disorder in a
patient, that is modulated by the therapeutic protein or its fragment or
variant. The compositions and methods of the invention are useful in
diagnosing, preventing, treating or ameliorating diseases or disorders,
such as HIV, osteoporosis, cancer, wounds, autoimmune diseases,
cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-
versus-host disease, stroke, atherosclerosis and inflammation. The
present sequence is used in the examples of the present invention.

ACCESSION NUMBER: ADD68005 peptide DGENE

TITLE: New **albumin fusion protein** for
diagnosing, preventing or treating diseases (e.g. HIV,
cancer, atherosclerosis or stroke) comprises a therapeutic
protein (e.g. cathepsin K or vascular endothelial growth
factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I) ROSEN C A.
(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-810996 [76]

DESCRIPTION: Yeast invertase (SU2) leader-hGH N-terminal fusion peptide.

L19 ANSWER 28 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing,
preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or
stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular
endothelial growth factor) and an albumin.

AN ADD68077 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any
of the therapeutic proteins listed in the specification, or their

fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68077 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.
(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-810996 [76]

DESCRIPTION: Human therapeutic protein #7.

L19 ANSWER 29 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

AN ADD68076 protein DGENE

AB The present invention relates to albumin fusion proteins comprising any of the therapeutic proteins listed in the specification, or their fragments or variants, and an albumin protein or its fragments or variants. The invention also discloses pharmaceutical compositions comprising the albumin fusion proteins, a kit comprising the albumin fusion proteins, and methods for treating a disease or disorder in a patient, that is modulated by the therapeutic protein or its fragment or variant. The compositions and methods of the invention are useful in diagnosing, preventing, treating or ameliorating diseases or disorders, such as HIV, osteoporosis, cancer, wounds, autoimmune diseases, cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-versus-host disease, stroke, atherosclerosis and inflammation. The present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68076 protein DGENE

TITLE: New **albumin fusion protein** for diagnosing, preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular endothelial growth factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.
(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English
OTHER SOURCE: 2003-810996 [76]
DESCRIPTION: Human therapeutic protein #6.

L19 ANSWER 30 OF 2840 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New **albumin fusion protein** for diagnosing,
preventing or treating diseases (e.g. HIV, cancer, atherosclerosis or
stroke) comprises a therapeutic protein (e.g. cathepsin K or vascular
endothelial growth factor) and an albumin.

AN ADD68071 peptide DGENE

AB The present invention relates to albumin fusion proteins comprising any
of the therapeutic proteins listed in the specification, or their
fragments or variants, and an albumin protein or its fragments or
variants. The invention also discloses pharmaceutical compositions
comprising the albumin fusion proteins, a kit comprising the albumin
fusion proteins, and methods for treating a disease or disorder in a
patient, that is modulated by the therapeutic protein or its fragment or
variant. The compositions and methods of the invention are useful in
diagnosing, preventing, treating or ameliorating diseases or disorders,
such as HIV, osteoporosis, cancer, wounds, autoimmune diseases,
cardiovascular diseases, hepatitis, multiple sclerosis, psoriasis, graft-
versus-host disease, stroke, atherosclerosis and inflammation. The
present sequence represents a human therapeutic protein.

ACCESSION NUMBER: ADD68071 peptide DGENE

TITLE: New **albumin fusion protein** for
diagnosing, preventing or treating diseases (e.g. HIV,
cancer, atherosclerosis or stroke) comprises a therapeutic
protein (e.g. cathepsin K or vascular endothelial growth
factor) and an albumin.

INVENTOR: Rosen C A; Haseltine W A

PATENT ASSIGNEE: (ROSE-I)ROSEN C A.

(HASE-I) HASELTINE W A.

PATENT INFO: US 2003125247 A1 20030703 180p

APPLICATION INFO: US 2001-833041 20010412

PRIORITY INFO: US 2000-229358P 20000412

US 2000-199384P 20000425

US 2000-256931P 20001221

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-810996 [76]

DESCRIPTION: Human therapeutic protein #1.